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1. Introduction 
This report describes and summarises results 
from the seventeenth proficiency test trial 
conducted by the National Food Institute (DTU 
Food) as the EU Reference Laboratory for 
Antimicrobial Resistance (EURL-AR). This 
proficiency test focuses on antimicrobial 
susceptibility testing (AST) of Salmonella and 
Campylobacter and is the eigth External Quality 
Assurance System (EQAS) conducted for these 
microorganisms (the first was EQAS 2006). In 
addition, the proficiency test for the sixth time 
includes an optional element consisting of 
genotypic characterization by PCR/sequencing 
of antimicrobial resistance genes. This optional 
component included characterization of genes 
related to production of AmpC, ESBL- and 
carbapenemases in the Salmonella test strains. 
This EQAS aims to: i) monitor the quality of 
AST results produced by National Reference 
Laboratories (NRL-AR), ii) identify laboratories 
which may need assistance to improve their 
performance in AST, and iii) determine possible 
topics for further research or collaboration. 
In reading this report, the following important 
considerations should be taken into account: 
1) Expected results were generated by 
performing Minimum Inhibitory Concentration 
(MIC) determinations for all test strains in two 
different occasions at the Technical University 
of Denmark, National Food Institute (DTU 
Food). These results were then verified by the 
United States Food and Drug Administration 
(FDA), Centre for Veterinary Medicine. Finally, a 
fourth MIC determination was performed at 
DTU Food after preparation of the agar stab 
culture for shipment to participants to confirm 
that the vials contained the correct strains with 
the expected MIC values. 
2) Evaluation is based on interpretations of 
AST values determined by the participants. This 
is in agreement with the method used by MS to 
report AST data to the European Food Safety 
Authority (EFSA), and complies with the main 
objective of this EQAS, i.e. “to assess and 
improve the comparability of surveillance and 
antimicrobial susceptibility data reported to 
EFSA by the different NRLs”, as stated in the 
protocol. 
3) The EURL-AR network agreed on setting the 
accepted deviation level for laboratory 
performance on AST to 5%. For the optional 
genotypic characterisation, no specific 
acceptance level has been set. 
Evaluation of a result as “deviating from the 
expected interpretation” should be carefully 
analyzed in a self-evaluation procedure 
performed by the participant and considering 
the introduction of corrective actions in the 
laboratory, if necessary. Note, that since 
methods used for MIC determination have 
limitations, it is not considered a mistake to 
obtain a one-fold dilution difference in the MIC 
of a specific antimicrobial when testing the 
same strains. If, however, the expected MIC is 
close to the breakpoint value for categorizing 
the strain as susceptible or resistant, a one-fold 
dilution difference - which is acceptable - may 
result in two different interpretations, i.e. the 
same strain can be categorized as susceptible 
and resistant. This result will be evaluated as 
correct in one case and incorrect in the other if 
the evaluation is based on interpretation of MIC 
values. This report is based on evaluation of 
AST interpretations, therefore some participants 
may find their results classified as incorrect 
even though the actual MIC they reported is 
only a one-fold dilution different from the 
expected MIC. In these cases, the participants 
should be confident about the good quality of 
their performance of AST by MIC. In the 
organization of the EQAS, we try to avoid these 
situations by choosing test strains with MIC 
values distant from the breakpoints for 
resistance, which is not always feasible for all 
strains and all antimicrobials. Therefore, the 
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EURL-AR network unanimously established in 
2008 that if there are less than 75% correct 
results for a specific strain/antimicrobial 
combination, the reasons for this situation must 
be further examined and, on selected occasions 
explained in details case by case, these results 
may subsequently be subtracted from the 
evaluation report.  
This report is approved in its final version by a 
technical advisory group composed by 
competent representatives from all NRL-ARs. 
This group meets annually at the EURL-AR 
workshop. 
All conclusions presented in this report are 
publically available. Participating laboratories 
are identified by codes and each code is known 
only by the corresponding laboratory. The full 
list of laboratory codes is confidential 
information known only by relevant 
representatives of the EURL-AR and the EU 
Commission.  
The EURL-AR is accredited by DANAK as 
provider of proficiency testing (accreditation no. 
516); working with zoonotic pathogens and 
indicator organisms as bacterial isolates 
(identification, serotyping and antimicrobial 
susceptibility testing). 
2. Materials and Methods  
2.1 Participants in EQAS 2014 
A pre-notification (App. 1) to announce the 
EURL-AR EQAS on AST of Salmonella and 
Campylobacter was distributed on the 30th June 
2014 by e-mail to the 43 NRLs in the EURL-AR-
network including all EU countries and Iceland, 
Norway, Serbia, Switzerland and Turkey. One 
laboratory from Spain did not participate as they 
had neither Salmonella nor Campylobacter AST 
as their field of responsibility. One NRL from 
France did not participate as they perform AST 
by disk diffusion and for this EQAS, results 
obtained by MICs, only, are accepted. 
Therefore results from one laboratory was 
excluded from the evaluation, since they were 
not obtained by dilution methods in the full 
range of antimicrobial concentrations specified 
in Decision 2013/652/EU. The NRL from Serbia 
did not participate in this year’s iteration. In 
addition to the AST of Salmonella and 
Campylobacter, an optional genotypic 
characterization by PCR/sequencing of 
antimicrobial resistance genes of the AmpC-, 
ESBL- and carbapenemase-producing 
Salmonella test strains was offered.  
Appendix 2 shows that 35 of the 40 
participating NRLs were appointed by the 
individual Member States’ Competent Authority. 
Eight additional laboratories were included; one 
from each of the following countries: Denmark, 
Iceland, the Netherlands, Norway, Serbia, 
Spain, Switzerland, and Turkey. These were 
invited to take part in the EQAS 2014 on the 
basis of their participation in previous EQAS 
iterations and/or affiliation to the EU network. 
These laboratories were charged a fee for their 
participation in the EQAS, whereas the NRLs 
from EU Member States participated free of 
charge. 
Figure 1 illustrates that of the 32 participating 
countries, 31 tested both Salmonella and 
Campylobacter. One country uploaded 
Salmonella results, only, for evaluation 
(Turkey). Eleven laboratories  participated in the 
optional genotypic characterisation of the ESC-
producing Salmonella test strains (not 
illustrated in Figure 1; see Appendix 2). 
The results from the NRLs designated by the 
MS are presented and evaluated in this report 
in addition to national reference laboratories in 
affiliated non-MS; i.e. results from 32 countries 
consisting of 35 laboratories submitting 
Salmonella results and 32 laboratories 
submitting Campylobacter results. Results from
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Figure 1: Participating countries that performed antimicrobial susceptibility testing of Salmonella or both 
Salmonella and Campylobacter. 
the three laboratories not designated by the MS 
but enrolled on equal terms as these are not 
further presented or evaluated in this report. 
2.2 Strains  
Eight Salmonella strains and eight 
Campylobacter strains were selected for this 
trial among isolates from the strain collection at 
DTU Food on the basis of antimicrobial 
resistance profiles and MIC values. For quality 
assurance purposes, one strain per bacterial 
species has been included in all EQAS 
iterations performed to date, representing an 
internal control. 
Prior to distribution of the strains, AST was 
performed on the Salmonella and 
Campylobacter strains at DTU Food and 
verified by the US Food and Drug 
Administration (FDA). When MIC-values were 
not in agreement but varied +/- one MIC-step, 
the value obtained by DTU Food was selected 
as the reference value. The obtained MIC 
values served as reference for the test strains 
(App. 3a and 3b). Results from the following 
antimicrobials were not verified by FDA: 
cefepime, cefotaxime, cefotaxime/clavulanic 
acid, ceftazidime, ceftazidime/clavulanic acid, 
colistin, ertapenem, imipenem, meropenem, 
temocillin, tigecycline and trimethoprim for 
Salmonella and furthermore, streptomycin for 
Campylobacter. 
Reference strains Escherichia coli CCM 3954 
(ATCC 25922) and Campylobacter jejuni CCM 
6214 (ATCC 33560) were provided to new 
participating laboratories with instructions to 
store and maintain them for quality assurance 
purposes and future EQAS trials. 
2.3 Antimicrobials  
The antimicrobials tested in this EQAS are 
listed in the protocol (App. 4b).  
The antimicrobials tested correspond to the 
panel of antimicrobials listed in Decision 
2013/652/EU.  
Guidelines for performing AST were set 
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according to the Clinical and Laboratory 
Standards Institute (CLSI) document; M7-A9 
(2012) “Methods for Dilution Antimicrobial 
Susceptibility Tests for Bacteria That Grow 
Aerobically; Approved Standard - Ninth Edition”; 
M100-S24 (2014) “Performance Standards for 
Antimicrobial Susceptibility Testing” (Twenty-
Fourth Informational Supplement) and 
document VET01-A4 (2013) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Approved Standard – Fourth Edition). 
MIC results were interpreted by using the 
interpretative criteria listed in Decision 
2013/652/EU. Where values were not available, 
the list of interpretative criteria was 
supplemented with EUCAST epidemiological 
cut-off values (www.eucast.org) or CLSI-
interpretative criteria as described and indicated 
in the protocol (App. 4). No interpretative 
criteria were available to determine the 
interpretation of MIC-values from testing of 
azithromycin, cefepime and temocillin. Results 
of ESC detection tests were interpreted 
according to the most recent EFSA 
recommendations (EFSA Journal 2012; 
10(6):2742).  
The selection of antimicrobials used in the trial 
for Salmonella were: ampicillin (AMP), 
azithromycin (AZI), cefepime (FEP), cefotaxime 
(FOT), cefotaxime/clavulanic acid (FOT/Cl), 
cefoxitin (FOX), ceftazidime (TAZ), 
ceftazidime/clavulanic acid (TAZ/Cl), 
chloramphenicol (CHL), ciprofloxacin (CIP), 
colistin (COL), ertapenem (ERT), gentamicin 
(GEN), imipenem (IMI), meropenem (MER), 
nalidixic acid (NAL), sulfonamides 
(sulfamethoxazole) (SMX), tetracycline (TET), 
tigecycline (TGC), temocillin (TRM) and 
trimethoprim (TMP). 
Minimum Inhibitory Concentration (MIC) 
determination of the Salmonella test strains was 
performed using the Sensititre system from 
Trek Diagnostic Systems Ltd, UK. For ESC 
confirmatory test, the analysis included MIC 
determination by microbroth dilution.  
For Campylobacter the following antimicrobials 
were included: ciprofloxacin (CIP), erythromycin 
(ERY), gentamicin (GEN), nalidixic acid (NAL), 
streptomycin (STR), and tetracycline (TET). 
MIC determination was performed using the 
Sensititre systems from Trek Diagnostic 
Systems Ltd, UK, according to guidelines from 
the CLSI document M45-A2 (2010) “Methods 
for Antimicrobial Dilution and Disk Susceptibility 
Testing of Infrequently Isolated or Fastidious 
Bacteria” (Approved Guideline – Second 
Edition) and VET01-S2 (2013) “Performance 
Standards for Antimicrobial Disk and Dilution 
Susceptibility Tests for Bacterial Isolated From 
Animals” (Second Informational Supplement). 
Participants of the Campylobacter EQAS were 
additionally requested to identify the species of 
the Campylobacter spp. as either C. jejuni or C. 
coli. 
2.4 Distribution 
On the 14th October 2014, bacterial strains in 
agar stab cultures (Salmonella spp.) or charcoal 
swabs in transport media (Stuarts) 
(Campylobacter spp.) together with a welcome 
letter (App. 4a) were dispatched in double pack 
containers (class UN 6.2) to the participating 
laboratories according to the International Air 
Transport Association (IATA) regulations as 
UN3373, biological substances category B.  
2.5 Procedure 
Protocols and all relevant information were 
uploaded on the EURL-AR website 
(http://www.eurl-ar.eu), thereby EQAS 
participants could access necessary information 
at any time.  
Participants were instructed to subculture 
charcoal swabs immediately, store the agar 
stabs 4ºC (dark) and the freeze-dried strains 
cool and dark until performance of AST. 
Information related to the handling of the test 
strains and reference strains (App. 4b, c, d, e) 
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was made available. Participants receiving an 
ATCC reference strain were requested to save 
and maintain this strain for future proficiency 
tests. 
The participants were instructed to apply the 
interpretative criteria listed in the protocol (App. 
4). Instructions for interpretation of AST results 
allowed for categorization of results as resistant 
or susceptible. Categorisations as ‘intermediate’ 
were not accepted.  
The EURL-AR is aware that there are two 
different types of interpretative criteria of 
results, clinical breakpoints and epidemiological 
cut-off values. The terms ‘susceptible’, 
‘intermediate’ and ‘resistant’ should be reserved 
for classifications made in relation to the 
therapeutic application of antimicrobial agents. 
When reporting data using epidemiological cut-
off values, bacteria should be reported as ‘wild-
type’ or ‘non-wild-type’ (Schwarz et al., 2010). 
Due to the different methods of AST used by 
the participants and also to simplify the 
interpretation of results, throughout this report, 
we will still maintain the terms susceptible and 
resistant, even in cases where we are referring 
to wild-type and non-wild-type strains. 
As regards the method for performing the 
antimicrobial susceptibility testing, the protocol 
referred to Decision 2013/652/EU and 
instructed participants to perform a dilution 
method, i.e. microbroth dilution or agar dilution. 
Results obtained by methods not complying 
with the description in Decision 2013/652/EU 
were disregarded in the present analysis. 
A mandatory part of the proficiency test was to 
detect ESC-producing strains and interpret 
results according to the most recent EFSA 
recommendations (EFSA Journal 2012; 
10(6):2742) as described in the protocol.  
Results from QC reference strains would 
consist of MIC values for the reference strains 
E. coli (ATCC 25922) and C. jejuni (ATCC 
33560). The results were evaluated towards the 
quality control ranges according to the relevant 
guidelines; i.e. the CLSI documents VET01-S2 
(2013) or M100-S24 (2014) (App. 5). 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 
participating laboratories were requested to 
report the genes conferring resistance to 
extended-spectrum beta lactam antimicrobials. 
The organizers, however, decided to include 
none-ESC TEM-genes resulting in blaTEM-1 
registered as an expected gene, also. The 
genes listed in the table in the protocol (App. 
4b) were included in the test. Identification of 
additional genes not listed in the protocol was 
not evaluated by the database. The results 
were evaluated based on the actual genes and 
variants identified. 
The participating laboratories were encouraged 
to use their own laboratory’s method(s) for the 
genotypic characterisation. The expected 
results for this component of the EQAS were 
obtained by whole-genome-sequencing and 
subsequent analysis using the ResFinder 2.1 
platform available at 
http://cge.cbs.dtu.dk/services/ResFinder/. The 
positive identification of genes was not verified 
elsewhere. 
All participating laboratories were invited to 
enter the obtained results into an electronic 
record sheet at the EURL-AR web-based 
database through a secured individual login and 
password. The record sheet contained space 
for reporting the results obtained for the QC 
reference strains. Alternatively, it was offered 
the possibility to fill-in a record sheet (provided 
with the protocol) and to send it to the EURL-
AR by fax, mail or email. 
In addition, participants were encouraged to 
complete an evaluation form available at the 
EURL-AR database with the aim to improve 
future EQAS trials. 
The database was finally closed and 
evaluations were made available to participants 
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on the 17th February 2015. After this date, the 
participants were invited to login to retrieve an 
individual, database-generated report which 
contained an evaluation of the submitted results 
including possible deviations from the expected 
interpretations. Deviations in the interpretation 
as resistant or susceptible were categorised as 
‘incorrect’, as were also deviations concerning 
confirmation of an isolate as extended spectrum 
beta-lactamase- (ESBL-), ampC- or 
carbapenemase-producer. 
3. Results 
The participants were asked to report results, 
i.e. MIC values and the categorisation as 
resistant or susceptible. Only the categorisation 
was evaluated, whereas the MIC values were 
used as supplementary information. 
3.1 Data omitted from the report 
As mentioned in the introduction, the EURL-AR 
network established that data should be 
examined and possibly omitted from the 
general analysis if there are less than 75% 
correct results based on strain/antimicrobial 
combination (see Appendix 8 for an overview of 
correct/incorrect results). In the present EQAS 
this occurred in two cases which have been 
examined and consequently omitted from the 
analysis; 1) S9.8/colistin (expected 
interpretation was ‘susceptible’, however, 36% 
(12 laboratories) found the strain resistant to 
colistin. All except one presented MIC values 
only one step from the expected; 2)   
C9.6/tetracycline (expected interpretation was 
‘resistant’, however, 67% of participants found 
the strain ‘susceptible’ to tetracycline. In this 
case, there was no obvious reason why there 
were so few results in concordance with the 
expected. Both these combinations were 
subsequently omitted from further analysis. 
Additional combinations that presented a low 
level of concordance with the expected were S-
9.5/meropenem (66%) and S-9.7/tigecycline 
(71%). These data could indicate possible 
difficulties with the testing, and will therefore be 
included in the analysis presented in this report.  
3.2 Methods  
The agar dilution method and MIC 
determination were evaluated together as they 
are both quantitative methods giving results 
corresponding to the MIC of the bacterial strain 
tested.  
In the Salmonella trial, 34 laboratories 
performed microbroth dilution and one 
performed agar dilution). For the 
Campylobacter trial, 31 laboratories performed 
microbroth dilution and one performed agar 
dilution).  
Two panels of antimicrobials were included in 
the testing of the Salmonella strains; the test 
strains found resistant to cefotaxime, 
ceftazidime or meropenem on the first panel 
were additionally tested on the second panel 
according to the protocol indications aiming at 
concluding on the strain’s presumptive ESBL, 
AmpC or carbapenemase phenotype. 
3.3 Deviations, overall 
The list of deviations is shown in Appendix 8a 
and 8b. Figure 2 shows the total percentage of 
deviations from the expected results of AST 
performed by participating laboratories. The 
internal control strains mainly followed the trend 
in deviation level of the different EQAS trials 
(Figure 2). The deviation level in 2014 is 
acceptable for both the Salmonella and the 
Campylobacter trials. For both microorganisms, 
however, it appears that there has been a slight 
increase in the level of deviations, to 2.4% for 
Salmonella and 4% for Campylobacter. For 
Campylobacter, this increase can be explained
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Figure 2: A comparison between the EURL-AR EQAS’s since 2006, showing the total percentage of deviations 
for antimicrobial susceptibility testing performed by participating laboratories.  
by two laboratories’ high deviation levels (at 
34.0% and 22.9%). 
3.3.1 Salmonella trial  
For the Salmonella strains, 97.6% of the AST’s 
were interpreted correctly. The number of AST’s 
performed and the percentage of correct results 
for the individual strains in the EQAS, are listed 
in Table 1. Variations of obtained correct results 
ranged from 94.8-99.8% for Salmonella. Table 2 
illustrates the percentage of correct AST per 
antimicrobial by bacterial species. The level of 
correct AST was at 88.9% and 90.6% for 
imipenem and meropenem, but otherwise 
above 96.7% for the Salmonella test strains.  
ESC-producing Salmonella test strains 
Confirmation of beta-lactamase production is a 
mandatory component of this EQAS.  
According to the protocol, which was based on 
the EFSA recommendations, the confirmatory 
test for ESC-production requires use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone 
and in combination with a -lactamase inhibitor 
for either antimicrobial agent tested in 
combination with clavulanic acid vs. its MIC 
when tested alone (three dilution steps 
difference; MIC FOT:CTX/Cl or TAZ:TAZ/Cl ratio 
8) (CLSI M100 Table 2A; Enterobacteriaceae). 
Participants were instructed to test strains 
presenting resistance to cefotaxime (FOT), 
ceftazidime (TAZ or meropenem (MERO) on 
the second panel of antimicrobials. 
The classification of the phenotypic results was 
based on the most recent EFSA 
recommendations (EFSA 2012), indicating: 
 Presumptive ESBL-phenotype: strains 
with positive synergy test, susceptible to 
cefoxitin and resistant to cefepime 
 Presumptive ESBL+pAmpC-phenotype: 
strains with positive or negative synergy 
test, resistant to cefoxitin and resistant to 
cefepime 
 Presumptive pAmpC phenotype: strains 
with negative synergy test resistant to 
cefoxitin and susceptible to cefepime 
 Presumptive carbapenemase phenotype: 
strain resistant to meropenem 
 Unusual phenotype: any other 
combinations 
In this EQAS, all laboratories uploaded results 
for the strains harbouring resistance to the 
cephalosporins tested. 
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The strain S-9.3 was a pAmpC-producer, S-9.4 
was an ESBL-producer whereas S-9.5 and S-
9.6 were carbapenemase producers. Note that 
when categorizing the presumptive phenotypes, 
the interpretation of the cefepime result had to 
be disregarded, as no interpretative criteria 
were available.  
In total the categorization as ESBL-, pAmpC- or 
carbapenemase-producer was incorrect in 21 
cases, with two of the incorrect results 
submitted for S9.7 which was not resistant to 
cephalosporins or carbapenems. One 
laboratory (#39) presented four deviations in 
relation to the ESC-production of the test 
strains. Six other laboratories each presented 
two incorrect results (#23, #26, #29, #41, #42, 
and #58).  
Three laboratories (#32, #41 and #42) 
categorized strain S-9.3 (presumptive pAmpC-
phenotype based on negative synergy test with 
clavulanate and resistance to cefoxitin) as 
presumptive ESBL + pAmpC phenotype. One of 
the laboratories had interpreted the MIC for 
cefepime at 0.25 mg/L as ‘resistant’ but for the 
other two laboratories, no results on the second 
panel could indicate the background for this 
categorization. 
Two laboratories (#23 and #39) found strain S-
9.4 (presumptive ESBL-phenotype based on 
positive synergy test with clavulanate and 
susceptibility to cefoxitin) to be an ‘unusual 
phenotype and one laboratory (#29) indicated 
that it was not ESBL, AmpC- or 
carbapenemase-producing. The submitted 
results from the second panel from these three 
laboratories were all evaluated as ‘correct’ and 
therefore could not indicate why this 
categorization had been selected. 
For the strains S-9.5 and S-9.6 (presumptive 
carbapanemase phenotypes based on 
resistance to meropenem), seven laboratories 
(#23, #26, #29, #36, #39, #57, #58) and six 
(#26, #33, #37, #39, #42, #58), respectively, 
had selected and incorrect category. S-9.5 was 
incorrectly categorized as ‘unusual phenotype’ 
and ‘presumptive pAmpC’, whereas S-9.6 was 
incorrectly categorized as ‘unusual phenotype’ 
and ‘no ESBL, AmpC- or carbapenemase’. 
Laboratory #29 and #58 found S-9.5 and S-9.6, 
respectively, resistant to meropenem, but 
categorized the strain as ‘unusual phenotype’. 
Laboratory #39 did not report results for 
meropenem for the first panel, and discovered 
no meropenem resistance for either of the two 
strains in the second panel. One laboratory 
(#26) had detected meropenem in the first but 
not the second panel and one (#37) had not 
detected meropenem resistance in the first 
panel and therefore did not proceed with tested 
of the second panel. For neither of the 
remaining of the laboratories with incorrect 
categorizations for S-9.5 and S-9.6, none had 
detected meropenem-resistance for the first or 
the second panel. The obtained MIC-results for 
S-9.5 and S-9.6 were at <0.03 or 0.12 for the 
first panel, and at 0.12 or <=1 for the second 
panel.  
3.3.2 Campylobacter trial 
For the Campylobacter strains, 96.0% of AST’s 
were correctly tested. Table 1 presents that the 
variation in the obtained correct results ranged 
from 92.4-98.7% and Table 2 illustrates that the 
percentage of correct AST per antimicrobial 
was above 94.4% for the Campylobacter test 
strains with tetracycline exhibiting the lowest 
level. 
The participants were requested to identify the 
Campylobacter species. All 32 laboratories 
delivered in total 256 results of which seven 
identifications were incorrect. Three 
laboratories presented two deviations each 
(#19, #36, and #40). 
3.4 Deviations by laboratory 
Figure 3 and 4 illustrate the percentage of 
deviations for each participating laboratory. The 
laboratories are ranked according to their 
performance determined by the percentage of   
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Table 1. The number of AST performed and the percentage of correct results for each strain of Salmonella and 
Campylobacter. 
EQAS 2014 – Salmonella  EQAS 2014 – Campylobacter 
Test strain AST in total % correct  Test strain AST in total % correct 
S-9.1 448 98.9  C-9.1 (C. jejuni) 191 98.4 
S-9.2 448 98.0  C-9.2 (C. coli) 184 92.4 
S-9.3 659 99.2  C-9.3 (C. coli) 185 96.2 
S-9.4 652 98.2  C-9.4 (C. jejuni) 179 98.3 
S-9.5 655 94.8  C-9.5 (C. jejuni) 185 94.1 
S-9.6 637 95.4  C-9.6 (C. coli) 159 98.7 
S-9.7 446 98.0  C-9.7 (C. jejuni) 179 93.3 
S-9.8 415 99.8  C-9.8 (C. coli) 191 96.9 
 
Table 2: Percentage of correct antimicrobial 
susceptibility tests per antimicrobial by 
microorganism.  
Antimicrobial Salmonella Campylobacter 
Ampicillin 100 - 
Cefotaxime 99.0 - 
Cefoxitin 97.8  
Ceftazidime 98.3 - 
Chloramphenicol 99.6 - 
Ciprofloxacin 98.6 96.0 
Colistin 98.0 - 
Ertapenem 97.0 - 
Erythromycin - 95.6 
Gentamicin 99.6 98.4 
Imipenem 88.9 - 
Meropenem 90.6 - 
Nalidixic acid 97.1 95.6 
Streptomycin - 95.9 
Sulphonamides 98.9 - 
Tetracycline 100 94.4 
Tigecycline 96.7 - 
Trimethoprim 98.9 - 
 
deviating results in the antimicrobial 
susceptibility tests. 
3.4.1 Salmonella trial  
Thirty-three of the 35 participating laboratories 
obtained a result within the acceptance limit at 
5% deviations for the Salmonella strains. The 
maximum percentage of deviations was 9.4%. 
The performance of two (6%) laboratories 
resulted in a deviation level above the level of 
performance expected by the EURL-AR (#57 
and #58), however, none of the laboratories are 
regarded as outliers. 
3.4.2 Campylobacter trial 
In the Campylobacter trial, most laboratories 
performed very well. Applying the 5% 
acceptance threshold, 24 of 32 participating 
laboratories performed acceptably, with 17 
laboratories having no deviations (Figure 4). 
Eight laboratories present a deviation level 
above the 5% acceptance level (#19, #29, #34, 
#36, #39, #40, #42, and #58). Of these, the two 
with deviation levels at 22.9% and 34.0% were 
regarded as outliers (#29, and #40). 
3.5 Deviations by reference strains  
In the following section, deviations are defined 
as results of antimicrobial susceptibility tests on 
the reference strain that are outside the quality 
control (QC) acceptance intervals (App. 5).  
Values from the participants’ testing of the QC 
strains are listed in Appendix 6a and 6b, and in 
Table 4-5. For both the Salmonella and 
Campylobacter trial, all laboratories uploaded 
data from QC-testing on the relevant reference 
strain. 
Appendix 6a indicates that of the 26 
laboratories submitting AST-results for the 
reference strain E. coli ATCC 25922, nine 
                                                            
 
13 
 
Table 3: Overview of ESBL-, pAmpC- and carbapenemase-producing Salmonella test strains and proportion of 
laboratories that obtained the expected result; number and percentages of laboratories which correctly detected and 
confirmed the ESBL-, pAmpC- and carbapenemase-producing Salmonella strains. Fields shaded in grey with numbers in 
italics indicate an unexpected result. 
 Strain S-9.3 Strain S-9.4 Strain S-9.5 Strain S-9.6 
ESC-genes harboured in the test strain blaCMY-2 
blaCTX-M-9 
blaTEM-1 
blaVIM-2 
blaTEM-1 
blaOXA-48 
ESBL-, pAmpC- and carbapenemase-producing 
strain – expected results 
pAmpC ESBL carbapenemase carbapenemase 
Obtained 
results 
Confirmed ESBL-producer - 32/35 (91%) - - 
Confirmed ESBL + pAmpC-producer 3/35 (9%) - - - 
Confirmed pAmpC-producer 32/35 (91%) - 4/35 (11%) - 
Confirmed carbapenemase-producer - - 28/35 (80%) 29/35 (83%) 
Confirmed unusual phenotype - 2/35 (6%) 3/35 (9%) 4/35 (11%) 
Not ESBL-, pAmpC-  
or carbapenemase-producing - 1/35 (3%) - 2/35 (6%) 
 
 
Figure 3: Individual participants’ deviations in percent of their total number of Salmonella AST’s.  
 
Figure 4: Individual participants’ deviations in percent of their total number of Campylobacter AST’s. 
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Table 4 Obtained values for AST of E. coli ATCC 25922. 
AMP; ampicillin, FEP; cefepime FOT; cefotaxime, FOX; 
cefoxitin, TAZ; ceftazidime, CHL; chloramphenicol, CIP; 
ciprofloxacin, COL; colistin, ERT: ertapenem, GEN; 
gentamicin, IMI; imipenem, MER; meropenem, NAL; 
nalidixic acid, SMX; sulphonamides, TET; tetracycline, 
TGC; tigecycline, TMP; trimethoprim. 
MIC determination E. coli ATCC 25922 
Antimicrobial 
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above upper 
QC limit 
Panel 1, AMP 1/35 (3%) - 3 steps 
Panel 1, FOT 2/34 (6%) - 6 steps 
Panel 1, TAZ 1/34 (3%) - 3 steps 
Panel 1, CHL 0/35 (0%) - - 
Panel 1, CIP 1/35 (3%) - 2 steps 
Panel 1, COL 0/35 (0%) - - 
Panel 1, GEN 1/35 (3%) 2 steps - 
Panel 1, MER 0/34 (0%) - - 
Panel 1, NAL 0/35 (0%) - - 
Panel 1, SMX 2/24 (8%) - 1 step 
Panel 1, TET 0/35 (0%) - - 
Panel 1, TGC 0/32 (0%) - - 
Panel 1, TMP 4/35 (11%) 1 step 1 step 
Panel 2, FEP 1/27 (4%) - 4 steps 
Panel 2, FOT 1/24 (4%) - 3 steps 
Panel 2, FOX 2/26 (8%) 1 step 3 steps 
Panel 2, TAZ 1/26 (4%) - 3 steps 
Panel 2, ERT 1/27 (4%) - 1 step 
Panel 2, IMI 0/28 (0%) - - 
Panel 2, MER 0/28 (0%) - - 
 
Figure 5: Individual participants’ deviations in percent of 
their total number of results from the genotypic 
characterization.  
Table 5 Obtained values for AST of C. jejuni ATCC 33560. 
CIP; ciprofloxacin, ERY; erythromycin, GEN; gentamicin, 
NAL; nalidixic acid, TET; tetracycline. 
MIC determination C. jejuni ATCC 33560 
Antimicrobial
Proportion 
outside QC 
range 
Obtained values in MIC 
steps (min/max) 
Below 
lower QC 
limit 
Above upper 
QC limit 
CIP 2/32 (6%) - 1 step 
ERY 0/32 (0%) - - 
GEN 2/29 (7%) 2 steps - 
NAL 0/31 (0%) - - 
TET 4/31 (13%) - 2 steps 
laboratories produced in all 18 values outside 
the QC-limit. Of these, eight could be attributed 
to one laboratory obtaining MIC-values several 
two-fold dilutions above the QC-range (#57). 
Table 4 illustrates the obtained results which 
are shown in full in Appendix 6a.  
Table 5 presents the proportion of laboratories 
with results for the C. jejuni reference strain 
ATCC 33560 below or above the QC interval. 
eight deviations were seen, all from different 
laboratories. 
3.6 Genotypic characterisation 
For the optional genotypic characterisation of 
the ESC-producing Salmonella test strains, 
eleven laboratories participated. In Appendix 9, 
information is collected on detected genes, 
genes which were tested but not detected, 
primers used, and references for the method 
used. Two laboratories performed whole 
genome sequencing of the ESC-producing 
Salmonella, the remaining nine laboratories 
indicated the use of various types of 
conventional PCR to identify the relevant 
genes. 
Table 6 indicate the obtained results, both on 
gene and variant level. Moreover, Figure 5 
indicates that the discordant results were 
submitted by one laboratory (#32). This 
laboratory should evaluate the procedure to 
assess how the relevant test could be improved 
in the future. 
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Table 6: Results from the participation of eleven laboratories in the optional genotypic characterisation component of the 
EQAS 
Test strain Expected gene Proportion of correct results (gene level) 
Proportion of correct 
results (variant level) 
Additional genes/variants 
identified 
S-9.3 CMY-2 11/11 (100%) 10/10 (100%)   
S-9.4 
CTX-M-9 11/11 (100%) 8/9 (89%) 
CTX M-14 
TEM-1 8/8 (100%) 5/5 (100%) 
S-9.5 
VIM-2 10/10 (100%) 7/7 (100%)  
  TEM-1 5/5 (100%) 3/3 (100%) 
S-9.6 OXA-48 10/10 (100%) 10/10 (100%) VIM* 
*Participant informed that this gene was not detected, but was incorrectly introduced to the database. 
 
4. Discussion 
It is important to consider that the number of 
EQAS participants differs from year to year, 
which implies that comparisons among different 
EQAS iterations should be interpreted with 
caution.  
As also specified in the EU regulation 
2013/652/EU, all participants in the present 
EQAS performed AST by dilution methods, 
primarily as microbroth determination.  
4.1 Salmonella trial  
Overall, the percentage of correct antimicrobial 
susceptibility test results of Salmonella was 
97.6%. The majority (n=33) of participants 
obtained satisfactory results according to the 
level of acceptance (<5% deviation).  
As indicated in Figure 2, the overall quality of 
the results in the 2014-EQAS would appear to 
have decreased slightly, whereas the measure 
when comparing results obtained from testing 
the internal control strain indicates a steady and 
very good quality of results.  
This proficiency test is the first possibility of 
testing the strains with the panels designed to 
follow the requirements of Decision 
2013/652/EU. For the testing of Salmonella test 
strains, imipenem and meropenem both 
presented low levels of concordance with the 
expected (88.9% and 90.6%, respectively) 
which also affects the deviation level in the 
context of categorization of pAmpC-, ESBL-, 
and carbapenemase phenotypes.  
As indicated by Figure 3, deviation levels higher 
than 5% were exhibited by two laboratories 
(#57 and #58). Laboratory #57 in particular 
obtained deviating results related to S-9.5 
which was also incorrectly categorized as a 
presumptive pAmpC instead of a presumptive 
carbapanemase phenotype. For laboratory #58, 
the 12 deviations also had deviating results in 
relation to S-9.5 for meropenem and imipenem, 
but the remaining deviations were due to 
detection of a high MIC-level and a 
categorization as resistant where the expected 
result was susceptible. In fact, this also was the 
case when looking at the results obtained by 
laboratory #58 in the 2013-iteration. Both 
laboratories presenting deviation levels above 
5% have been contacted by the EURL-AR to 
discuss and work towards improving the quality 
of results. None of these laboratories were 
defined as outliers. 
For the E. coli reference strain, the obtained 
results were in general in agreement with the 
CLSI recommendations. Disregarding the 
laboratory that obtained eight of the 18 values 
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outside of the QC-ranges, trimethoprim and 
sulfamethoxazole appeared to be the 
antimicrobials causing problems with some of 
the values above and some below the QC-
range.   
For the two laboratories #42, and #57 which 
had a deviation level above the acceptance limit 
in EQAS 2013 with values of 5.3% and 7.4%, 
respectively, one has this year increased their 
performance (#42) to a deviation level at 2.4%, 
and the other (#57) present has a deviation 
level at 9.4% in the 2014-iteration.  
ESC-producing Salmonella test strains 
The detection of ESC-producing 
microorganisms remain to be important and is a 
mandatory part of this EQAS.  
Of the four Salmonella test strains relevant for 
this component of the EQAS (S-9.3, S-9.4, S-
9.5, and S-9.6), one was a pAmpC-phenotype, 
one was an ESBL-phenotype and two were 
carbapenemase phenotypes. The testing and 
interpretation of results in particular caused 
difficulties for the two carbapenemase 
producing strains where meropenem resistance 
would be the reason to classify this strain as a 
carbapenemase-producer. The expected 
meropenem MIC was at 1 mg/L and 0.5 mg/L 
for S-9.5 and S-9.6, respectively. These were 
both more than one dilution step above the 
cutoff-value (at 0.125 mg/L), however, still only 
80% and 83% of the participating laboratories 
could detect the carbapenemase production in 
these strains. Three laboratories indicated the 
MIC result for meropenem to be <=1 mg/L when 
testing the second panel, indicating that some 
laboratories do not test the range required by 
Decision 2013/652/EU (0.03-16 mg/L for 
meropenem). With a cutoff value at 0.125 mg/L, 
a range of concentration with the lowest at 1 
mg/L gives difficulties in detecting resistance 
and therefore also in detecting carbapenemase 
production. These results present examples of 
issues which the NRLs face when performing 
laboratory testing of ESC-producing strains and 
will be brought up for discussion in the network 
to discuss which tools to apply to obtain better 
analysis and interpretation.  
Of the 35 laboratories which tested Salmonella, 
one (#39) submitted results which were 
incorrect for four test strains in relation to ESC-
production. This laboratory has been contacted 
by the EURL-AR to identify possible causes of 
this unsatisfactory performance and to improve 
the quality of results. 
Laboratory #57 which had one deviation for the 
categorization as ESBL-, pAmpC- or 
carbapenemase-producers (S-9.5) obtained a 
high number of incorrect AST-results in the 
Salmonella strains and also in the E. coli QC-
reference strain, indicating that there could 
issues related to the handling of the strains or 
other procedures in the laboratory that would 
need a review.   
For the test strains S-9.3 and S-9.4 which were 
pAmpC-phenotype and ESBL-phenotype, the 
six results not in concordance with the expected 
appeared to relate to the interpretation of the 
obtained MIC-values, as there could not be 
detected any discordance when comparing the 
obtained and expected MIC-values. The six 
results were reported by six different 
laboratories. 
4.2 Campylobacter trial  
For the Campylobacter component of this 
year’s EQAS, 32 laboratories submitted results 
leading to an overall percentage of correct AST 
results at 96.0%. The performance varied from 
no deviations up to 34.0% deviations, with 24 
laboratories performing satisfactorily according 
to the established acceptance range.  
For both microorganisms, it appears that there 
has been a slight increase in the level of 
deviations, to 2.4% for Salmonella and 4% for 
Campylobacter. 
Eight laboratories (#19, #29, #34, #36, #39, 
#40, #42, and #58) obtained deviation levels 
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above 5%, two of these were defined as outliers 
(#29 and #40) with deviation levels at 22.9% 
and 34.0%. For none of these laboratories, the 
values obtained for the QC-strain indicate 
methodical issues to be the reason for the 
obtained deviations. Two reported that they 
suspect a switch of strains in the laboratory to 
have been the cause of the deviation. The two 
outliers have been requested to investigate and 
report the cause of the high number of 
deviations. The EURL-AR awaits responses in 
this regard.  
Laboratory #19 obtained three deviations when 
testing C-9.7 and three when testing C-9.8 
which indicates the testing of two other strains, 
possibly a switch or contaminants. Laboratory 
#29 presents eight deviations of which seven 
have a higher MIC than expected and therefore 
are categorized as resistant. Four of the 
deviations are related to the same test strain 
(C-9.2). Laboratory #34 suspected a cut and 
paste-error, whereas #36 suspected a switch of 
strains, but due to a heavy work load a re-
testing has not yet been performed. Laboratory 
#39 and #42 both reported an expected MIC 
value which was incorrectly interpreted. 
Laboratory #40 presented 16 deviating results 
of which four, five and three related to strains C-
9.2, C-9.5 and C-9.8. Laboratory #58 presented 
six deviations, all relating to the same strain (C-
9.5), and all obtaining interpretations as 
resistant instead of susceptible, which could 
indicate a switch of strains. All eight 
laboratories presenting deviation levels above 
5% have been contacted by the EURL-AR to 
identify possible causes of this unsatisfactory 
performance and to improve the quality of 
results. 
All participating laboratories uploaded data from 
tests performed on the C. jejuni reference strain 
and the proportion of results within the QC 
intervals was 94.8%. Six of the eight values 
outside the QC intervals were just one step 
below or above the QC-limits, the remaining 
two were two dilution steps above or below the 
QC-limits. The laboratories obtaining these 
values should monitor these over time to 
ensure that their tests render a reliable result 
for the particular antimicrobial. 
Laboratories #37, #6, and #22 which were 
regarded as outliers in EQAS 2013 with 
deviation levels at 12.5%, 14.6% and 19.0%, 
respectively, all increased their performance 
extensively in the 2014-iteration and obtained 
deviation levels at 0%, 0% and 0%, 
respectively. Laboratory #29 which in 2013 also 
was considered as an outlier with a deviation 
level at 12.5%, was again in 2014 considered 
as an outlier due to a deviation level at 22.9%. 
4.3 Genotypic characterisation 
The focus on genotypic characterization of 
microorganisms is increasing in the EU and 
worldwide. In EU, communication has been 
ongoing to improve laboratory detection and 
confirmation of ESBL- and pAmpC-producing 
Enterobacteriaceae.  
Furthermore, the agenda now is focusing at the 
implementation of detection of carbapenemase 
resistant organisms, with the recent EFSA 
Scientific Opinion (EFSA BIOHAZ Panel, 2013) 
describing the importance of determining the 
identity of the genes responsible for the 
carbapenemase production by molecular 
methods.  
The optional genotypic characterisation offered 
as a supplementary part of this EQAS should 
therefore be seen as an important possibility for 
the NRL-AR’s to introduce this method in the 
laboratory and thereby be at the forefront when 
the method proposals are adopted. This year, 
eleven laboratories participated in this optional 
EQAS component. 
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5. Conclusions 
The goal of the EURL-AR EQAS is to have all 
participating NRLs performing antimicrobial 
susceptibility testing of Salmonella and 
Campylobacter with a deviation level below 5%. 
This seems within reach for Salmonella as well 
as for Campylobacter.  
The performance of the NRL’s appear to be 
slightly lower for Salmonella AST’s in this EQAS 
(97.6%) when compared to the results from the 
previous EQAS 2011, 2012, and 2013 (98.1%, 
99.0%, and 99.3%). Regarding Campylobacter 
AST’s, the level of deviation appears to have 
risen and this year it reached a level of 4.0% 
compared to 1.9%, 2.1%, and 3.5% in 2011, 
2012, and 2013. Two laboratories have 
contributed substantially to this increase in the 
general deviation level in the Campylobacter 
AST as they were regarded as outliers (#29, 
and #40) and presented high deviation levels 
(22.9% and 34.0%).  
Eleven NRLs participated in the EQAS 
component consisting of genotypic testing of 
ESBL-, AmpC- and carbapenemase-producing 
Enterobacteriaceae. Improvement is needed to 
correctly identify the phenotype of Salmonella 
spp. producing beta-lactamases of the ESBL-, 
AmpC, and carbapenemase-type as this is a 
priority area within the EURL-AR activities. We 
strongly encourage participants having 
problems in identifying these strains to perform 
a re-test of the test strains as a training 
exercise and to contact the EURL-AR in case 
any discussion is needed. 
Finally, the EURL-AR is open to suggestions to 
improve future EQAS trials and invites the 
entire network to contribute with ideas for 
training courses and specific focus areas to 
expand the network’s knowledge in 
antimicrobial resistance. 
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EQAS 2014  
FOR SALMONELLA, CAMPYLOBACTER AND OPTIONAL GENOTYPIC CHARACTERISATION 
The EURL-AR announces the launch of another EQAS, thus providing the opportunity for 
proficiency testing which is considered an essential tool for the generation of reliable laboratory 
results of consistently good quality. 
This EQAS consists of antimicrobial susceptibility testing of eight Salmonella isolates and eight 
Campylobacter isolates. For the optional genotypic characterisation, the ESBL-genes in the relevant 
Salmonella strains should be detected. Additionally, quality control (QC) strains E. coli ATCC 
25922 (CCM 3954) and C. jejuni ATCC 33560 (CCM 6214) will be distributed to new participants.  
This EQAS is specifically for NRL’s on antimicrobial resistance. Therefore, laboratories designated 
to be NRL-AR do not need to sign up to participate but are automatically regarded as participants. 
You may contact the EQAS-Coordinator if you wish to inform of changes. Participation is free of 
charge for all above-mentioned designated laboratories.  
TO AVOID DELAY IN SHIPPING THE ISOLATES TO YOUR LABORATORY 
The content of the parcel is “UN3373, Biological Substance Category B”: Eight Salmonella strains, 
eight Campylobacter and, for new participants, also the QC strains mentioned above. Please provide 
the EQAS coordinator with documents or other information that can simplify customs procedures 
(e.g. specific text that should be written on the pro-forma invoice). To avoid delays, we kindly ask 
you to send this information already at this stage.  
TIMELINE FOR RESULTS TO BE RETURNED TO THE NATIONAL FOOD INSTITUTE 
Shipment of isolates and protocol: The isolates will be shipped in October 2014. The protocol for 
this proficiency test will be available for download from the website (www.eurl-ar.eu).  
Submission of results: Results must be submitted to the National Food Institute no later than 
December 5th 2014 via the password-protected website.  
Upon reaching the deadline, each participating laboratory is kindly asked to enter the password-
protected website once again to download an automatically generated evaluation report. 
EQAS report: A report summarising and comparing results from all participants will be issued. In 
the report, laboratories will be presented coded, which ensures full anonymity. The EURL-AR and 
the EU Commission, only, will have access to un-coded results. The report will be publicly 
available. 
 
Next EQAS: The next EURL-AR EQAS that we will have is on antimicrobial susceptibility testing 
of E. coli, staphylococci and enterococci which will be carried out in June 2015.  
Please contact me if you have comments or questions regarding the EQAS. 
Sincerely, 
 
 
Susanne Karlsmose (suska@food.dtu.dk) 
EQAS-Coordinator 
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Appendix 2, page 1 of 1
Participant list
Salmonella Campylobacter Genotypic characterisation Institute  Country
X X - Austrian Agency for Health and Food Safety Austria
X X X Institute of Public Health Belgium
X X - National Diagnostic and Research Veterinary Institute Bulgaria
X X - Croatian Veterinary Institut Croatia
X X - Veterinary Services Cyprus
X X X State Veterinary Institute Praha Czech Republic
X X X National Food Institute Denmark
X X - Danish Veterinary and Food Administration, DVFA Denmark
X X - Estonian Veterinary and Food Laboratory Estonia
X X - Finnish Food Safety Authority EVIRA Finland
X - - Agence nationale de sécurité sanitaire ANSES - Fougères LERMVD France
X - - Agence nationale de sécurité sanitaire ANSES - LERQAP France
- - - Agence nationale de sécurité sanitaire ANSES - Lyon France
- X - Agence nationale de sécurité sanitaire ANSES - Ploufragan - LERAP France
X X X Federal Institute for Risk Assessment Germany
X X - Veterinary Laboratory of Chalkis Greece
X X - Central Agricultural Office Veterinary Diagnostic Directorate Hungary
X X - University of Iceland Iceland
X X - Central Veterinary Research Laboratory Ireland
X X X Istituto Zooprofilattico Sperimentale delle Regioni Lazio e Toscana Italy
X X - Institute of Food Safety, Animal Health and Enviroment "BIOR" Latvia
X X - National Food and Veterinary Risk Assessment Institute Lithuania
X X X Laboratoire national de Santé Luxembourg
X X - Public Health Laboratory Malta
X X X Central Veterinary Institute of Wageningen UR Netherlands
X X - Food and Consumer Product Safety Authority (VWA) Netherlands
X X - Veterinærinstituttet Norway
X X X National Veterinary Research Institute Poland
X X - Laboratorio National de Investigacáo Veterinaria Portugal
X X - Institute for Diagnosis and Animal Health Romania
X X X Institute for Hygiene and Veterinary Public Health Romania
- - - Institute of Veterinary Medicine of Serbia Serbia
X X - State Veterinary and Food Institute  (SVFI) Slovakia 
X X - National Veterinary Institute Slovenia
X - - Centro nacional de Alimentacion. Agencia Espanola de Seguridad Alimentaria y Nutricion Spain
X X X Laboratorio Central de Sanidad, Animal de Algete Spain
- - - Laboratorio Central de Sanidad, Animal de Santa Fe Spain
X X - VISAVET Health Surveillance Center, Complutense University Spain
X X X National Veterinary Institute, SVA Sweden
X X - Vetsuisse Faculty Bern, Institute of Veterinary Bacteriology Switzerland
X - - National Food Reference Laboratory Turkey
- - - Public Health England - Colindale United Kingdom
X X - The Veterinary Laboratory Agency United Kingdom
Designated NRL-AR by the compentent authority of the member state
Non-NRL-AR enrolled by the EURL-AR
Not a Member State of the EU
Appendix 3a, page 1 of 1
Reference values (MIC-value and interpretation) - Salmonella 
Ampicillin Azithromycin Cefepime Cefotaxime Cefotaxime/clav F:F/C Cefoxitin Ceftazidime Ceftazidime/clav T:T/C Chloramphenicol Ciprofloxacin Colistin Ertapenem
AMP AZI FEP FOT F/C ratio FOX TAZ T/C ratio CHL CIP COL ETP
EURL S-9.1  = 1 SUSC  = 8 -  <= 0.25 SUSC  <= 0.5 SUSC  <= 8 SUSC  = 0.03 SUSC  = 8 RESIST
EURL S-9.2  > 64 RESIST  = 8 -  <= 0.25 SUSC   <= 0.5 SUSC  <= 8 SUSC  = 0.5 RESIST  <= 1 SUSC
EURL S-9.3  > 64 RESIST  = 8 -  = 0.25 -  = 16 RESIST  = 8/4 -  <8  = 32 RESIST  = 16 RESIST  = 8/4 -  <8  = 128 RESIST  = 0.03 SUSC  <= 1 SUSC  <= 0.015 SUSC
EURL S-9.4  > 64 RESIST  = 8 -  = 2 -  = 16 RESIST  = 0.12/4 -  >=8  = 2 SUSC  = 1 SUSC  = 0.25/4 -  <8  <= 8 SUSC  = 0.5 RESIST  <= 1 SUSC  <= 0.015 SUSC
EURL S-9.5  > 64 RESIST  = 8 -  = 2 -  > 64 RESIST  > 64/4 -  <8  > 64 RESIST  = 64 RESIST  = 64/4 -  <8  <= 8 SUSC  > 8 RESIST  <= 1 SUSC  = 0.5 RESIST
EURL S-9.6  > 64 RESIST  = 32 -  = 0.12 -  = 0.5 SUSC  = 0.25/4 -  <8  = 8 SUSC  = 0.5 SUSC  = 0.25/4 -  <8  <= 8 SUSC  = 8 RESIST  <= 1 SUSC  = 0.25 RESIST
EURL S-9.7  > 64 RESIST  = 16 -  <= 0.25 SUSC  <= 0.5 SUSC  <= 8 SUSC  = 0.06 SUSC  <= 1 SUSC
EURL S-9.8  <= 1 SUSC  = 8 -  <= 0.25 SUSC  <= 0.5 SUSC  <= 8 SUSC <= 0.015 SUSC  = 2 SUSC
Gentamicin Imipenem Meropenem Nalidixic acid Sulfamethoxazole Temocillin Tetracycline Tigecycline Trimethoprim
GEN IMI MER NAL SMX TRM TETRA TGC TMP
EURL S-9.1  <= 0.5 SUSC  = 0.06 SUSC  <= 4 SUSC  = 32 SUSC  <= 2 SUSC  <= 0.25 SUSC  <= 0.25 SUSC
EURL S-9.2  > 32 RESIST  = 0.06 SUSC  = 32 RESIST  = 128 SUSC  <= 2 SUSC  <= 0.25 SUSC  <= 0.25 SUSC
EURL S-9.3  <= 0.5 SUSC  = 0.25 SUSC  <= 0.03 SUSC  <= 4 SUSC  > 1024 RESIST  = 8 -  > 64 RESIST  = 0.5 SUSC  <= 0.25 SUSC
EURL S-9.4  <= 0.5 SUSC  = 0.25 SUSC  <= 0.03 SUSC  > 128 RESIST  = 64 SUSC  <= 4 -  = 32 RESIST  <= 0.25 SUSC  <= 0.25 SUSC
EURL S-9.5  = 32 RESIST  = 4 RESIST  = 1 RESIST  > 128 RESIST  > 1024 RESIST  > 128 -  = 64 RESIST  = 0.5 SUSC  <= 0.25 SUSC
EURL S-9.6  <= 0.5 SUSC  = 1 SUSC  = 0.5 RESIST  > 128 RESIST  = 16 SUSC  > 128 -  <= 2 SUSC  = 0.5 SUSC  <= 0.25 SUSC
EURL S-9.7  <= 0.5 SUSC  <= 0.03 SUSC  <= 4 SUSC  > 1024 RESIST  > 64 RESIST  = 2 RESIST  > 32 RESIST
EURL S-9.8  = 1 SUSC  <= 0.03 SUSC  <= 4 SUSC  = 16 SUSC  <= 2 SUSC  <= 0.25 SUSC  <= 0.25 SUSC
Resistant
OXA-48
N/A
N/A
CMY-2
No ESBL, AmpC- or carbapenemase
No ESBL, AmpC- or carbapenemase
ESBL-category Relevant genes
N/A
N/A
No ESBL, AmpC- or carbapenemase
No ESBL, AmpC- or carbapenemase
Presumptive pAmpC-phenotype
Presumptive ESBL-phenotype
Presumptive carbapenemase phenotype
Presumptive carbapenemase phenotype
TEM-1; CTXM-9
TEM-1; VIM-2
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Reference values (MIC-value and interpretation) - Campylobacter 
Ciprofloxacin Erythromycin Gentamicin Nalidixic acid Streptomycin Tetracycline
Species Code CIP ERY GEN NAL STR TET
C. jejuni EURL C-9.1  = 8 RESIST  <= 1 SUSC  = 0.25 SUSC  > 64 RESIST  = 0.5 SUSC  > 64 RESIST
C. coli EURL C-9.2  = 0.25 SUSC  > 128 RESIST  = 0.5 SUSC  = 8 SUSC  = 1 SUSC  = 2 SUSC
C. coli EURL C-9.3  > 16 RESIST  = 4 SUSC  = 0.25 SUSC  > 64 RESIST  > 16 RESIST  > 64 RESIST
C. jejuni EURL C-9.4  > 16 RESIST  > 128 RESIST  > 16 RESIST  > 64 RESIST  > 16 RESIST  > 64 RESIST
C. jejuni EURL C-9.5  <= 0.12 SUSC  <= 1 SUSC  = 0.25 SUSC  = 4 SUSC  = 1 SUSC  <= 0.5 SUSC
C. coli EURL C-9.6  = 4 RESIST  > 128 RESIST  = 1 SUSC  = 64 RESIST  > 16 RESIST  = 4 RESIST
C. jejuni EURL C-9.7  = 16 RESIST  <= 1 SUSC  = 0.25 SUSC  = 2 SUSC  = 0.5 SUSC  <= 0.5 SUSC
C. coli EURL C-9.8  <= 0.12 SUSC  > 128 RESIST  = 1 SUSC  = 8 SUSC  > 16 RESIST  = 1 SUSC
Resistant
 
 
 
 
Appendix 4a, page 1 of 1 
M00-06-001/01.12.2011  
 
EURL-AR External Quality Assurance System 2014 
- Salmonella, Campylobacter and optional genotypic characterisation 
 
Id: «Lab_no_» 
«Name» 
«Institute__» 
«Country» 
Kgs. Lyngby, October 2014 
 
Dear «Name», 
 
Please find enclosed the bacterial strains for the EURL-AR EQAS 2014. Upon arrival to your 
laboratory, the strains should be stored dark and at 4C for stabs, and dark and cool for freeze-
dried strains. Charcoal swabs must be subcultured straight away.  
 
On the EURL-AR-website (www.eurl-ar.eu) the following documents relevant for the EURL-AR 
EQAS are available: 
- Protocol for Salmonella and Campylobacter including test forms 
- Instructions for Opening and Reviving Lyophilised Cultures 
- Subculture and Maintenance of Quality Control Strains 
 
We ask you to examine the eight Salmonella and the eight Campylobacter strains that we sent to 
you by performing antimicrobial susceptibility testing. The ESBL-producing Salmonella strains 
should be characterised genotypically (optional) according to the description in the protocol. In the 
protocol you can find detailed description of the procedures to follow. Additionally, you can find a 
description of the procedure to enter your results into the interactive web database. For accessing 
the database, you need this username and password. 
 
 
Your username: «Username» 
 
Your password: «Password» 
 
Please keep this document 
  Your username and password will not appear in other documents 
 
 
Results should be submitted to the database no later than December 5th 2014. 
 
Please acknowledge receipt of this parcel immediately upon arrival (to suska@food.dtu.dk).  
Do not hesitate to contact us for further information. 
 
Yours sincerely, 
 
Susanne Karlsmose 
EQAS-Coordinator 
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2014 
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PROTOCOL  
For antimicrobial susceptibility testing of Salmonella, Campylobacter and optional 
genotypic characterisation of AmpC-, ESBL- and carbapenemase-producing test strains 
 
1  INTRODUCTION  ................................................................................................................... 1 
2  OBJECTIVES  .......................................................................................................................... 2 
3  OUTLINE OF THE EQAS 2014  ............................................................................................ 2 
3.1    Shipping, receipt and storage of strains  ........................................................................ 2 
3.2  Suggested procedure for reconstitution of the lyophilised reference strains  ............ 2 
3.3  Antimicrobial susceptibility testing  .............................................................................. 2 
3.4  Optional genotypic characterisation  ............................................................................. 5 
4  REPORTING OF RESULTS AND EVALUATION  ........................................................... 6 
5  HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE  ............................. 6 
 
1 INTRODUCTION 
The organisation and implementation of an External Quality Assurance System (EQAS) on 
antimicrobial susceptibility testing (AST) of Salmonella and Campylobacter is among the tasks of 
the EU Reference Laboratory for Antimicrobial Resistance (EURL-AR). The Salm/Camp EQAS 
2014 will include AST of eight Salmonella and Campylobacter strains and AST of reference strains 
E. coli ATCC 25922 (CCM 3954) and C. jejuni ATCC 33560 (CCM 6214).  
The above-mentioned reference strains are included in the parcel only for new participants of the 
EQAS who did not receive them previously. The reference strains are original CERTIFIED cultures 
provided free of charge, and should be used for future internal quality control for antimicrobial 
susceptibility testing in your laboratory. The reference strains will not be included in the years to 
come. Therefore, please take proper care of these strains. Handle and maintain them as suggested in 
the manual ‘Subculture and Maintenance of QC Strains’ available on the EURL-AR website (see 
www.eurl-ar.eu).  
Various aspects of the proficiency test scheme may from time to time be subcontracted. When 
subcontracting occurs it is placed with a competent subcontractor and the National Food Institute is 
responsible to the scheme participants for the subcontractor’s work. 
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2 OBJECTIVES 
This EQAS aims to support laboratories to assess and, if necessary, to improve the quality of results 
obtained by AST of pathogens of food- and animal-origin, with special regard to Salmonella and 
Campylobacter. Further objectives are to evaluate and improve the comparability of surveillance 
data on antimicrobial susceptibility of Salmonella and Campylobacter reported to EFSA by 
different laboratories. 
3 OUTLINE OF THE EQAS 2014 
3.1    Shipping, receipt and storage of strains 
In October 2014, the National Reference Laboratories for Antimicrobial Resistance (NRL-AR) will 
receive a parcel containing eight Salmonella and Campylobacter strains from the National Food 
Institute. This parcel will also contain reference strains, but only for participants who did not 
receive them previously. All strains belong to UN3373, Biological substance, category B. Extended 
spectrum beta-lactamase (ESBL)-producing strains as well as carbapenamase producing strains are 
included in the selected material and are part of the optional EQAS-item, consisting of 
characterization of genes conferring ESBL- or carbapenemase production.  
The reference strains are shipped lyophilised, the Campylobacter test strains are shipped as a 
charcoal swabs and the Salmonella test strains are stab cultures. On arrival, the stab cultures and the 
charcoal swabs must be subcultured, and all cultures should be adequately stored until testing. A 
suggested procedure for reconstitution of the lyophilised reference strains is presented below. 
3.2 Suggested procedure for reconstitution of the lyophilised reference strains  
Please refer to the document ‘Instructions for opening and reviving lyophilised cultures’ on the 
EURL-AR-website (see www.eurl-ar.eu). 
3.3 Antimicrobial susceptibility testing 
The strains should be tested for susceptibility to the antimicrobials listed in Tables 1, 2 and 3, using 
the method implemented in your laboratory for performing monitoring for EFSA and applying the 
interpretative criteria listed below. 
Participants should perform minimum inhibitory concentration (MIC) determination using the 
methods stated in the EC regulation EC 652/2013. For interpretation of results, use the cut-off 
values listed in Tables 1, 2 and 3 (except where indicated) represent the current epidemiological 
cut-off values developed by EUCAST (www.eucast.org), and allow categorisation of bacterial 
isolates into two categories; resistant or susceptible. A categorisation as intermediate is not 
accepted.  
As the current regulation and recommendations focus on MIC testing only, disk diffusion results 
cannot be submitted. 
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3.3.1 Salmonella. 
The interpretative criteria that should be applied for categorizing the Salmonella test strain as 
resistant or susceptible are those listed in Tables 1 and 2.  
Table 1: Antimicrobials recommended for AST of Salmonella spp. and interpretative criteria according to 
table 1 in EC regulation 652/2013 
Antimicrobial MIC (g/mL) (R>) 
Ampicillin (AMP) 8 
Azithromycin (AZI) Not available* 
Cefotaxime (FOT) 0.5 
Ceftazidime (TAZ) 2 
Chloramphenicol (CHL) 16 
Ciprofloxacin (CIP) 0.06 
Colistin (COL) 2 
Gentamicin (GEN) 2 
Meropenem (MERO) 0.125 
Nalidixic acid (NAL) 16 
Sulfonamides (SMX) 256** 
Tetracycline (TET) 8 
Tigecycline (TGC) 1*** 
Trimethoprim (TMP) 2 
* Participants are requested to upload the MIC value obtained without selecting an interpretation.  
** CLSI M100 Table 2A 
*** Data from EUCAST is available for S. Enteritidis, S. Typhimurium, S. Typhi and S. Paratyphi. 
 
Table 2: Antimicrobials recommended for additional AST of Salmonella spp. resistant to cefotaxime, 
ceftazidime or meropenem and interpretative criteria according to table 4 in EC regulation 652/2013 
Antimicrobial MIC (g/mL) (R>) 
Cefepime, FEP Not available* 
Cefotaxime, FOT 0.5 
Cefotaxime + clavulanic acid (F/C) Not applicable 
Cefoxitin, FOX 8 
Ceftazidime, TAZ 2 
Ceftazidime+ clavulanic acid (T/C) Not applicable 
Ertapenem, ETP 0.06 
Imipenem, IMI 1 
Meropenem, MERO 0.125 
Temocillin, TRM Not available* 
* Participants are requested to upload the MIC value obtained without selecting an interpretation 
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Plasmid-mediated quinolone resistance  
When performing antimicrobial susceptibility testing of the Salmonella test strains, the 
interpretative criteria listed in Table 1 should be able to detect plasmid mediated quinolone resistant 
test strains.  
Extended-beta-lactam- and carbapenem resistance  
Confirmatory tests for AmpC-, ESBL- and carbapenemase production are mandatory on all strains 
resistant to cefotaxime (CTX), ceftazidime (TAZ) or meropenem and should be performed by 
testing the second panel of antimicrobials (Table 2 in this document corresponding to Table 4 in EC 
regulation 652/2013). 
Confirmatory tests for AmpC-, ESBL- and carbapenemase production require the use of both 
cefotaxime (FOT) and ceftazidime (TAZ) alone and in combination with a β-lactamase inhibitor 
(clavulanic acid). Synergy is defined either as a ≥ 3 twofold concentration decrease in an MIC for 
either antimicrobial agent tested in combination with clavulanic acid vs. its MIC when tested alone 
(MIC FOT : FOT/CL or TAZ : TAZ/CL ratio ≥ 8) (CLSI M100 Table 2A; Enterobacteriaceae). The 
presence of synergy indicates ESBL production. Resistance to cefepime gives further indication of 
ESBL production, but is not essential. Confirmatory test for carbapenemase production requires the 
testing of meropenem (MERO).  
Detection of AmpC-type beta-lactamases can be performed by testing the bacterium for 
susceptibility to cefoxitin (FOX). Resistance to FOX could indicate the presence of an AmpC-type 
beta-lactamase that may be verified by PCR and sequencing.  
The classification of the phenotypic results should be based on the most recent EFSA 
recommendations (EFSA 20121) indicating the strains as:  
 Presumptive ESBL: strains with positive synergy test, susceptible to cefoxitin and 
resistant to cefepime  
 Presumptive ESBL+pAmpC: strains with positive or negative synergy test, resistant to 
cefoxitin and resistant to cefepime  
 Presumptive pAmpC phenotype: strains with negative synergy test  
 Presumptive carbapenemase phenotype: strain resistant to meropenem  
 Unusual phenotype: any other combinations  
                                                          
1 European Food Safety Authority; Technical specifications on the harmonised monitoring and reporting of 
antimicrobial resistance in Salmonella, Campylobacter and indicator Escherichia coli and Enterococcus spp. bacteria 
transmitted through food. EFSA Journal 2012; 10(6):2742. [64 pp.] doi:10.2903/j.efsa.2012.2742. Available online:  
www.efsa.europa.eu/efsajournal  
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We recommend, however, that strains showing synergy with clavulanic acid for at least one of the 
third generation cephalosporins (cefotaxime or ceftazidime) should be considered ESBL-producing, 
independently of the cefepime result. 
3.3.2 Campylobacter   
For AST of Campylobacter, MIC methods should be applied, i.e. broth or agar dilution methods 
using incubation at 36-37ºC for 48 hours or 42ºC for 24 hours.  
Table 3: Antimicrobials recommended for AST of Campylobacter jejuni and C. coli and 
interpretative criteria according to table 1 in EC regulation 652/2013 
Antimicrobial C. jejuni C. coli 
MIC (g/mL) (R>) MIC (g/mL) (R>) 
Ciprofloxacin (CIP) 0.5 0.5 
Erythromycin (ERY) 4 8 
Gentamicin (GEN) 2 2 
Nalidixic acid (NAL) 16 16 
Streptomycin (STR) 4 4 
Tetracycline (TET) 1 2 
 
Identification of Campylobacter species 
Species identification of the Campylobacter test strains must be performed by the NRLs using in-
house methods or adopting the protocol available on the EURL-AR website under: http://eurl-
ar.eu/233-protocols.htm. 
3.4 Optional genotypic characterisation 
For the optional genotypic characterisation of the AmpC-, ESBL- or carbepenemase producing 
Salmonella test strains, the requested results are the genes conferring AmpC-, ESBL- or 
carbepenemase -production harboured in the test strains. The genes included in the test are the 
following: ACC, ACT, CMY, CTX, DHA, FOX, GES, IMP, KPC, MOX, NDM, OXA, PER, SHV, 
TEM, VEB, and VIM. The database lists the relevant variants of the genes.   
When uploading the results in the database, the identified genes will be evaluated against the 
expected results. The results will be evaluated on the detected gene (ACC-, ACT-, CMY-, etc.) as 
well as the variant identified.  
The method used for the genotypic characterisation should be your laboratory’s routine method. 
The expected results listed in the database are those obtained by the EURL-AR.  
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4 REPORTING OF RESULTS AND EVALUATION 
Test forms are available for recording your results before you enter them into the interactive web 
database.  
We recommend reading carefully the description reported in paragraph 5 before entering your 
results in the web database.  Results must be submitted no later than December 5th, 2014. After 
the deadline when all participants have uploaded results, you will be able to login to the database 
once again, and to view and print an automatically generated report evaluating your results. Results 
in agreement with the expected interpretation are categorised as ‘correct’, while results deviating 
from the expected interpretation are categorised as ‘incorrect’. 
If you experience difficulties in entering your results, please contact us directly.  
All results will be summarized in a report which will be publicly available. The data in the report 
will be presented with laboratory codes. A laboratory code is known to the individual laboratory, 
whereas the complete list of laboratories and their codes is confidential and known only to the 
EURL-AR and the EU Commission. All conclusions will be public. 
If you have questions, please do not hesitate to contact the EQAS Coordinator: 
Susanne Karlsmose 
National Food Institute 
Technical University of Denmark 
Kemitorvet, Building 204, DK-2800 Lyngby 
Denmark 
Tel: +45 3588 6601 
Fax: +45 3588 6341 
E-mail: suska@food.dtu.dk 
5 HOW TO ENTER RESULTS IN THE INTERACTIVE DATABASE 
Please read carefully this paragraph before entering the web page. 
Remember that you need by your side the completed test forms.  
Enter the EURL-AR EQAS 2014 start web page (http://eurl-ar.food.dtu.dk), write your username 
and password (lower-case) and press enter. Your username and password are indicated in the letter 
following your strains. Do not hesitate to contact us if you experience problems with the login. 
You can browse back and forth by using the Home or back keys, but please remember to save your 
inputs before. 
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Click on either “Salmonella test results” or “Campylobacter test results” for input of test results.  
Click on "Start of Data Entry - Methods” 
In the next page, you navigate among fields with the Tab-key and the mouse.  
Complete the fields related to the method used for antimicrobial susceptibility testing and the brand 
of MIC trays, etc.  
When submitting Campylobacter results, fill in the incubation conditions applied for susceptibility 
testing of Campylobacter – 36°C/48h or 42°C/24h. 
Click on "save and go to next page”  
In the data entry pages, you enter the species (for Campylobacter only), the obtained MIC-value 
and the interpretation (R, resistant or S, susceptible) for each Salmonella and Campylobacter strain. 
For Salmonella, remember to also report the results for the ESBL detection tests. 
If you did not test for susceptibility to a given antimicrobial, please leave the field empty. 
Click on "save and go to next page" 
When uploading data on the reference strains, please enter MIC values in µg/ml. Remember to use 
the operator keys to show symbols like “equal to”, etc. 
Click on “save“. 
Review the input pages by browsing through them and make corrections if necessary. Remember to 
save a page if you make corrections. If you press home a page without saving changes, you will see 
an error screen. In this case, click on “save“ to save your results, browse back to the page and then 
continue. 
Please complete the evaluation form. 
Before approving your input, please be sure that you have filled in all the relevant fields as  YOU 
CAN ONLY APPROVE ONCE!  The approval blocks your data entry in the interactive database.  
If you have performed the optional genotypic characterisation: 
Click on “Gene test” and follow the description in the database for upload of the results of the 
optional genotypic characterization. Approve your input. Be sure that you have filled in all the 
results before approval. The approval blocks your data entry in the interactive database, but allows 
you to see the submitted results. 
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Salmonella, Campylobacter and genetic characterisation 
 
TEST FORMS 
   
 
 
Name:       
 
Name of laboratory:       
 
Name of institute:       
 
City:       
 
Country:       
 
E-mail:       
 
Fax:       
 
 
Comments:       
  
EU Reference Laboratory for Antimicrobial Resistance  
External Quality Assurance System (EQAS) 2014 
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TEST FORM                                                            
 
Does your laboratory have an accreditation for performing Salmonella AST?   Yes     No 
 
Which method did you use for antimicrobial susceptibility testing of Salmonella in this EQAS: 
  Broth microdilution    
  Agar dilution 
 
 Brand of microbroth plates/agar:        
 Incubation conditions:      °C/     h 
 
How many Salmonella isolates does your laboratory annually isolate:       
 
How many Salmonella isolates does your laboratory annually test for antimicrobial susceptibility by 
a MIC method:       
 
Comments or additional information:       
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TEST FORM          
 
Does your laboratory have an accreditation for Campylobacter AST?  Yes     No 
 
 
Incubation conditions:     36-37ºC / 48h   42ºC / 24h 
 
Method used for antimicrobial susceptibility testing of Campylobacter in this EQAS:: 
 Broth microdilution 
 Agardilution 
 
Brand of microbroth plates/agar:       
Additional comments:       
 
How many Campylobacter isolates does your laboratory annually isolate:       
How many Campylobacter isolates does your laboratory annually susceptibility test:       
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TEST FORM                            
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 9.X 
Ampicillin, AMP                         
Azithromycin, AZI                   
Cefotaxime, FOT                    
Ceftazidime, TAZ                    
Chloramphenicol, CHL                    
Ciprofloxacin CIP                         
Colistin, COL                   
Gentamicin, GEN                    
Meropenem, MERO                   
Nalidixic acid, NAL                    
Sulfamethoxazole, SMX                   
Tetracycline, TET                    
Tigecycline, TGC                   
Trimethoprim, TMP                    
 
All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be 
included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or 
carbapenemase production. See further description in the protocol section ‘3.3.1 Salmonella’.                 
 
Strain Antimicrobial  Results and interpretation 
 
> 
MIC-value (μg/ml) S / R 
Salmonella 
EURL S. 9.X 
Cefepime, FEP                   
Cefotaxime, FOT                   
Cefotaxime + clavulanic acid (F/C)                   
Cefoxitin, FOX                   
Ceftazidime, TAZ                   
Ceftazidime+ clavulanic acid (T/C)                   
Ertapenem, ETP                   
Imipenem, IMI                   
Meropenem, MERO                   
Temocillin, TRM                   
 
 Presumptive ESBL 
 Presumptive ESBL+ pAmpC 
 Presumptive pAmpC 
 Presumptive carbapenemase 
 
 Unusual phenotype 
 No ESBL, AmpC- or carbapenemase 
 
Comments (include optional genotype or other results):       
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TEST FORM                                                            
 
Antimicrobial susceptibility testing of reference strain E. coli ATCC 25922 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
1st panel 
 
 
Ampicillin, AMP        
Azithromycin, AZT       
Cefotaxime, FOT       
Ceftazidime, TAZ       
Chloramphenicol, CHL       
Ciprofloxacin, CIP       
Colistin, COL       
Gentamicin, GEN       
Meropenem, MERO       
Nalidixic acid, NAL       
Sulfisoxazole, FIS*       
Tetracycline, TET       
Tigecycline, TGC       
Trimethoprim, TMP       
2nd panel Cefepime, FEP       
Cefotaxime, FOT       
Cefotaxime + clavulanic acid (F/C)       
Cefoxitin, FOX       
Ceftazidime, TAZ       
Ceftazidime+ clavulanic acid (T/C)       
Ertapenem, ETP       
Imipenem, IMI       
Meropenem, MERO       
Temocillin, TRM       
*The antimicrobial which is mentioned in the CLSI M100 performance standard as representative 
for the sulfonamides concerning acceptable limits for quality control strains (CLSI M100, Table 3) 
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TEST FORM                                                           
Strain Antimicrobial  Interpretation 
MIC-value (μg/ml) S / R 
Campylobacter 
EURL C. 9.1 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C. 9.2 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C. 9.3 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
Campylobacter 
EURL C. 9.4 
 
     C. jejuni 
 
     C. coli 
Ciprofloxacin             
Erythromycin             
Gentamicin             
Nalidixic Acid             
Streptomycin             
Tetracycline             
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TEST FORM                                                           
 
Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
36 °C/48 hours 
 
42 °C/24 hours 
 
 
C. jejuni ATCC 33560 
 
Ciprofloxacin             
Erythromycin             
Nalidixic Acid             
Tetracycline             
 
 
  
For Agar dilution: 
 
 Susceptibility testing of Campylobacter jejuni reference strain ATCC 33560 
 
Strain 
 
 
 
Antimicrobial  
 
MIC-value (μg/ml) 
 
C. jejuni ATCC 33560 
 
 
Ciprofloxacin       
Doxycycline        
Erythromycin        
Gentamicin       
Meropenem        
Nalidixic Acid        
Tetracycline       
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G00-06-001/01.10.2014 
TEST FORM – genotypic characterisation                                    
 
Genotypic characterisation of the test strains 
 
Strain code:  
      
Method used:        
If PCR-methods, additional information should be given below 
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Gene:       
 
 Found 
 Tested, not found 
 Published method , reference:       
 In-house method 
Primer used 5’→3’:       
Primer used 3’→5’:       
 
Comments:       
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INSTRUCTIONS FOR OPENING AND REVIVING 
LYOPHILISED CULTURES 
 
 
Manual from  Czech Collection of Microorganisms (CCM) 
 Masaryk University 
 Tvrdého 14 
 602 00 BRNO 
 Czech Republic 
 
Lyophilised cultures are supplied in vacuum-sealed ampoules. Care should be taken in opening the 
ampoule. All instructions given below should be followed closely to ensure the safety of the person 
who opens the ampoule and to prevent contamination of the culture. 
a. Check the number of the culture on the label inside the ampoule 
b. Make a file cut on the ampoule near the middle of the plug 
c. Disinfect the ampoule with alcohol-dampened gauze or alcohol-dampened cotton wool from 
just below the plug to the pointed end 
d. Apply a red-hot glass rod to the file cut to crack the glass and allow air to enter slowly into 
the ampoule 
e. Remove the pointed end of the ampoule into disinfectant 
f. Add about 0.3 ml appropriate broth to the dried suspension using a sterile Pasteur pipette 
and mix carefully to avoid creating aerosols. Transfer the contents to one or more suitable 
solid and /or liquid media 
g. Incubate the inoculated medium at appropriate conditions for several days 
h. Autoclave or disinfect effectively the used Pasteur pipette, the plug and all the remains of 
the original ampoule before discarding 
Please note that:  
 Cultures should be grown on media and under conditions as recommended in the CCM 
catalogue 
 Cultures may need at least one subculturing before they can be optimally used in experiments 
 Unopened ampoules should be kept in a dark and cool place! 
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SUBCULTURE AND MAINTENANCE OF    
QUALITY CONTROL STRAINS 
1.1 Purpose 
Improper storage and repeated subculturing of bacteria can produce alterations in antimicrobial 
susceptibility test results. The Clinical and Laboratory Standards Institute (CLSI, formerly NCCLS) 
has published a guideline for Quality Control (QC) stock culture maintenance to ensure consistent 
antimicrobial susceptibility test results. 
1.2 References 
M100-S21, January 2011 (Performance Standards for Antimicrobial Susceptibility Testing) 
M7-A8, January 2009 (Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That 
Grow Aerobically; Approved Standard) 
1.3 Definition of Terms 
Reference Culture: A reference culture is a microorganism preparation that is acquired from a 
culture type collection.  
Reference Stock Culture: A reference stock culture is a microorganism preparation that is derived 
from a reference culture. Guidelines and standards outline how reference stock cultures must be 
processed and stored.  
Working Stock Cultures: A working stock culture is growth derived from a reference stock culture. 
Guidelines and standards outline how working stock cultures must be processed and how often they 
can be subcultured.  
Subcultures (Passages): A subculture is simply the transfer of established microorganism growth on 
media to fresh media. The subsequent growth on the fresh media constitutes a subculture or 
passage. Growing a reference culture or reference stock culture from its preserved status (frozen or 
lyophilized) is not a subculture. The preserved microorganism is not in a stage of established 
growth until it is thawed or hydrated and grown for the first time 
1.4 Important Considerations 
 Do not use disc diffusion strains for MIC determination. 
 Obtain QC strains from a reliable source such as ATCC 
 CLSI requires that QC be performed either on the same day or weekly (only after 30 day QC 
validation) 
 Any changes in materials or procedure must be validated with QC before implemented 
 For example: Agar and broth methods may give different QC ranges for drugs such as 
glycopeptides, aminoglycosides and macrolides 
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 Periodically perform colony counts to check the inoculum preparation procedure 
 Ideally, test values should be in the middle of the acceptable range 
 Graphing QC data points over time can help identify changes in data helpful for 
troubleshooting problems 
1.5 Storage of Reference Strains 
Preparation of stock cultures 
 Use a suitable stabilizer such as 50% fetal calf serum in broth, 10-15% glycerol in tryptic 
soy broth, defibrinated sheep blood or skim milk to prepare multiple aliquots. 
 Store at -20°C, -70°C or liquid nitrogen. (Alternatively, freeze dry.) 
 Before using rejuvenated strains for QC, subculture to check for purity and viability. 
Working cultures 
 Set up on agar slants with appropriate medium, store at 4-8°C and subculture weekly. 
 Replace the working strain with a stock culture at least monthly. 
 If a change in the organisms inherent susceptibility occurs, obtain a fresh stock culture or a 
new strain from a reference culture collection e.g. ATCC. 
1.6 Frequency of Testing 
Weekly vs. daily testing  
Weekly testing is possible if the lab can demonstrate satisfactory performance with daily testing as 
follows: 
 Documentation showing reference strain results from 30 consecutive test days were within 
the acceptable range. 
 For each antimicrobial/organism combination, no more than 3 out of 30 MIC values may be 
outside the acceptable range. 
When the above are fulfilled, each quality control strain may be tested once a week and whenever 
any reagent component is changed. 
Corrective Actions  
If an MIC is outside the range in weekly testing, corrective action is required as follows: 
 Repeat the test if there is an obvious error e.g. wrong strain or incubation conditions used 
 If there is no obvious error, return to daily control testing 
The problem is considered resolved only after the reference strain is tested for 5 consecutive days 
and each drug/organism result is within specification on each day. 
If the problem cannot be resolved, continue daily testing until the errors are identified. 
Repeat the 30 days validation before resuming weekly testing. 
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DAILY MIC QC CHART 
 
Reference: CLSI M7-A8, page 44 
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WEEKLY MIC QC CHART 
 
 
Reference: CLSI M7-A8, page 45 
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Quality Control ranges for ATCC reference strains
Antimicrobial Microbroth      (36-37°C/48h)
Microbroth 
(42°C/24h)
Agar dilution   
(36-37°C/48h)
Agar dilution   
(42°C/24h)
Ciprofloxacin, CIP 0.06-0.25 0.03-0.12 0.12-1 0.06-0.5
Erythromycin, ERY 0.5-2 0.25-2 1-8 1-4
Gentamicin, GEN 0.5-2 0.25-2 0.5-2 0.5-4
Nalidixic acid, NAL 4-16 4-16 None None
Tetracycline, TET 0.25-2 0.25-1 None None
Campylobacter jejuni ATCC 33560
MIC ranges (µg/mL)  are according to CLSI (VET01-S2) 
Tigecycline, TGC 0.03-0.25
Trimethoprim, TMP 0.5-2
MIC ranges (µg/mL) are according to CLSI M100 S24 (range for ciprofloxacin and ertapenem 
extended to include 0.016).
Sulfisoxazole, FIS 8-32
Temocillin, TRM none
Tetracycline, TET 0.5-2
Imipenem, IMI 0.06-0.25
Meropenem, MERO 0.008-0.06
Nalidixic acid, NAL 1-4
Colistin, COL 0.25-2
Ertapenem, ETP 0.004-0.016
Gentamicin, GEN 0.25-1
Ceftazidime + clavulanic acid, T/C none
Chloramphenicol, CHL 2-8
Ciprofloxacin, CIP 0.004-0.016
Cefotaxime + clavulanic acid, F/C none
Cefoxitin, FOX 2-8
Ceftazidime, CAZ 0.06-0.5
Azithromycin, AZT none
Cefepime, FEP 0.015-0.12
Cefotaxime, FOT 0.03-0.12
E. coli ATCC 25922
Antimicrobial MIC
Ampicillin, AMP 2-8
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Test results from the reference strain E. coli ATCC 25922
Lab no. Panel Antimicrobial Operator Value Low limit High limit Mark Method
1 Panel 1 Ampicillin = 4 2 8 1 MIC
1 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
1 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
1 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
1 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
1 Panel 1 Colistin <= 1 0.25 2 1 MIC
1 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
1 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
1 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
1 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
1 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
1 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
1 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
1 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
1 Panel 2 Cefoxitin = 2 2 8 1 MIC
1 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
1 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
1 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
1 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
2 Panel 1 Ampicillin = 4 2 8 1 MIC
2 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
2 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
2 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
2 Panel 1 Ciprofloxacin = 0.06 0.004 0.016 0 MIC
2 Panel 1 Colistin <= 1 0.25 2 1 MIC
2 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
2 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
2 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
2 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
2 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
2 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
2 Panel 1 Trimethoprim = 5 0.5 2 0 MIC
2 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
2 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
2 Panel 2 Cefoxitin = 2 2 8 1 MIC
2 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
2 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
2 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
2 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
4 Panel 1 Ampicillin = 8 2 8 1 MIC
4 Panel 1 Cefotaxime = 0.25 0.03 0.125 0 MIC
4 Panel 1 Ceftazidime = 0.5 0.06 0.5 1 MIC
4 Panel 1 Chloramphenicol = 8 2 8 1 MIC
4 Panel 1 Ciprofloxacin = 0.015 0.004 0.016 1 MIC
4 Panel 1 Colistin = 1 0.25 2 1 MIC
4 Panel 1 Gentamicin = 0.5 0.25 1 1 MIC
4 Panel 1 Meropenem = 0.03 0.008 0.06 1 MIC
4 Panel 1 Nalidixic acid = 4 1 4 1 MIC
4 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
4 Panel 1 Tetracycline = 2 0.5 2 1 MIC
4 Panel 1 Tigecycline = 0.25 0.03 0.25 1 MIC
4 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
6 Panel 1 Ampicillin = 4 2 8 1 MIC
6 Panel 1 Cefotaxime < 0.25 0.03 0.125 1 MIC
6 Panel 1 Ceftazidime < 0.5 0.06 0.5 1 MIC
6 Panel 1 Chloramphenicol < 8 2 8 1 MIC
6 Panel 1 Ciprofloxacin < 0.015 0.004 0.016 1 MIC
6 Panel 1 Colistin < 1 0.25 2 1 MIC
6 Panel 1 Gentamicin < 0.5 0.25 1 1 MIC
6 Panel 1 Meropenem < 0.03 0.008 0.06 1 MIC
6 Panel 1 Nalidixic acid < 4 1 4 1 MIC
6 Panel 1 Tetracycline < 2 0.5 2 1 MIC
6 Panel 1 Tigecycline < 0.25 0.03 0.25 1 MIC
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6 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
6 Panel 2 Cefepime < 0.06 0.015 0.125 1 MIC
6 Panel 2 Cefotaxime < 0.25 0.03 0.125 1 MIC
6 Panel 2 Cefoxitin = 2 2 8 1 MIC
6 Panel 2 Ceftazidime < 0.25 0.06 0.5 1 MIC
6 Panel 2 Ertapenem < 0.015 0.004 0.016 1 MIC
6 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
6 Panel 2 Meropenem < 0.03 0.008 0.06 1 MIC
9 Panel 1 Ampicillin = 4 2 8 1 MIC
9 Panel 1 Ceftazidime <= 5 0.06 0.5 1 MIC
9 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
9 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
9 Panel 1 Colistin <= 1 0.25 2 1 MIC
9 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
9 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
9 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
9 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
9 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
9 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
9 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
9 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
9 Panel 2 Cefoxitin = 4 2 8 1 MIC
9 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
9 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
9 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
9 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
11 Panel 1 Ampicillin = 4 2 8 1 MIC
11 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
11 Panel 1 Ceftazidime <= 0.25 0.06 0.5 1 MIC
11 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
11 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
11 Panel 1 Colistin <= 1 0.25 2 1 MIC
11 Panel 1 Gentamicin <= 0.05 0.25 1 0 MIC
11 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
11 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
11 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
11 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
11 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
11 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
11 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
11 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
11 Panel 2 Cefoxitin = 2 2 8 1 MIC
11 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
11 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
11 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
11 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
12 Panel 1 Ampicillin = 4 2 8 1 MIC
12 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
12 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
12 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
12 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
12 Panel 1 Colistin <= 1 0.25 2 1 MIC
12 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
12 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
12 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
12 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
12 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
12 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
12 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
12 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
12 Panel 2 Cefoxitin = 4 2 8 1 MIC
12 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
12 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
12 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
12 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
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13 Panel 1 Ampicillin = 4 2 8 1 MIC
13 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
13 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
13 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
13 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
13 Panel 1 Colistin <= 1 0.25 2 1 MIC
13 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
13 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
13 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
13 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
13 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
13 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
13 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
13 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
13 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
13 Panel 2 Cefoxitin = 2 2 8 1 MIC
13 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
13 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
13 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
13 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
16 Panel 1 Ampicillin = 4 2 8 1 MIC
16 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
16 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
16 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
16 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
16 Panel 1 Colistin <= 1 0.25 2 1 MIC
16 Panel 1 Gentamicin = 1 0.25 1 1 MIC
16 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
16 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
16 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
16 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
16 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
16 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
16 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
16 Panel 2 Cefoxitin = 4 2 8 1 MIC
16 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
16 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
16 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
16 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
17 Panel 1 Ampicillin = 4 2 8 1 MIC
17 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
17 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
17 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
17 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
17 Panel 1 Colistin <= 1 0.25 2 1 MIC
17 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
17 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
17 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
17 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
17 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
17 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
17 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
17 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
17 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
17 Panel 2 Cefoxitin = 4 2 8 1 MIC
17 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
17 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
17 Panel 2 Imipenem <= 0.125 0.06 0.25 1 MIC
17 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
18 Panel 1 Ampicillin = 4 2 8 1 MIC
18 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
18 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
18 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
18 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
18 Panel 1 Colistin <= 1 0.25 2 1 MIC
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18 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
18 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
18 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
18 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
18 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
18 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
18 Panel 1 Trimethoprim = 5 0.5 2 0 MIC
19 Panel 1 Ampicillin = 4 2 8 1 MIC
19 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
19 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
19 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
19 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
19 Panel 1 Colistin <= 1 0.25 2 1 MIC
19 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
19 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
19 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
19 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
19 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
19 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
19 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
20 Panel 1 Ampicillin = 8 2 8 1 MIC
20 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
20 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
20 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
20 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
20 Panel 1 Colistin <= 1 0.25 2 1 MIC
20 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
20 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
20 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
20 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
20 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
20 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
20 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
20 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
20 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
20 Panel 2 Cefoxitin = 4 2 8 1 MIC
20 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
20 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
20 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
20 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
21 Panel 1 Ampicillin = 2 2 8 1 MIC
21 Panel 1 Cefotaxime < 0.25 0.03 0.125 1 MIC
21 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
21 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
21 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
21 Panel 1 Colistin = 1 0.25 2 1 MIC
21 Panel 1 Gentamicin = 0.5 0.25 1 1 MIC
21 Panel 1 Meropenem = 0.03 0.008 0.06 1 MIC
21 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
21 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
21 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
21 Panel 1 Tigecycline = 0.25 0.03 0.25 1 MIC
21 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
21 Panel 2 Cefepime = 0.12 0.015 0.125 1 MIC
21 Panel 2 Cefotaxime < 0.25 0.03 0.125 1 MIC
21 Panel 2 Cefoxitin = 2 2 8 1 MIC
21 Panel 2 Ceftazidime = 0.25 0.06 0.5 1 MIC
21 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
21 Panel 2 Imipenem = 0.12 0.06 0.25 1 MIC
21 Panel 2 Meropenem = 0.03 0.008 0.06 1 MIC
22 Panel 1 Ampicillin = 4 2 8 1 MIC
22 Panel 1 Cefotaxime < 0.25 0.03 0.125 1 MIC
22 Panel 1 Ceftazidime < 0.5 0.06 0.5 1 MIC
22 Panel 1 Chloramphenicol < 8 2 8 1 MIC
22 Panel 1 Ciprofloxacin < 0.015 0.004 0.016 1 MIC
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22 Panel 1 Colistin < 1 0.25 2 1 MIC
22 Panel 1 Gentamicin = 1 0.25 1 1 MIC
22 Panel 1 Meropenem < 0.03 0.008 0.06 1 MIC
22 Panel 1 Nalidixic acid < 4 1 4 1 MIC
22 Panel 1 Tetracycline < 2 0.5 2 1 MIC
22 Panel 1 Tigecycline < 0.25 0.03 0.25 1 MIC
22 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
22 Panel 2 Cefoxitin = 4 2 8 1 MIC
22 Panel 2 Ceftazidime < 0.5 0.06 0.5 1 MIC
22 Panel 2 Ertapenem < 0.015 0.004 0.016 1 MIC
22 Panel 2 Imipenem < 0.12 0.06 0.25 1 MIC
22 Panel 2 Meropenem < 0.03 0.008 0.06 1 MIC
23 Panel 1 Ampicillin = 4 2 8 1 MIC
23 Panel 1 Cefotaxime < 0.25 0.03 0.125 1 MIC
23 Panel 1 Chloramphenicol < 8 2 8 1 MIC
23 Panel 1 Ciprofloxacin < 0.015 0.004 0.016 1 MIC
23 Panel 1 Colistin < 1 0.25 2 1 MIC
23 Panel 1 Gentamicin = 1 0.25 1 1 MIC
23 Panel 1 Meropenem < 0.03 0.008 0.06 1 MIC
23 Panel 1 Nalidixic acid < 4 1 4 1 MIC
23 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
23 Panel 1 Tetracycline < 2 0.5 2 1 MIC
23 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
23 Panel 2 Cefepime < 0.06 0.015 0.125 1 MIC
23 Panel 2 Imipenem < 0.12 0.06 0.25 1 MIC
23 Panel 2 Meropenem < 0.03 0.008 0.06 1 MIC
25 Panel 1 Ampicillin = 4 2 8 1 MIC
25 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
25 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
25 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
25 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
25 Panel 1 Colistin <= 1 0.25 2 1 MIC
25 Panel 1 Gentamicin = 1 0.25 1 1 MIC
25 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
25 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
25 Panel 1 Sulfisoxazole <= 8 8 32 1 MIC
25 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
25 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
25 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
26 Panel 1 Ampicillin = 2 2 8 1 MIC
26 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
26 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
26 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
26 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
26 Panel 1 Colistin <= 1 0.25 2 1 MIC
26 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
26 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
26 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
26 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
26 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
26 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
29 Panel 1 Ampicillin = 4 2 8 1 MIC
29 Panel 1 Cefotaxime = 0.12 0.03 0.125 1 MIC
29 Panel 1 Ceftazidime = 0.5 0.06 0.5 1 MIC
29 Panel 1 Chloramphenicol < 8 2 8 1 MIC
29 Panel 1 Ciprofloxacin < 0.015 0.004 0.016 1 MIC
29 Panel 1 Colistin = 1 0.25 2 1 MIC
29 Panel 1 Gentamicin = 0.5 0.25 1 1 MIC
29 Panel 1 Meropenem < 0.03 0.008 0.06 1 MIC
29 Panel 1 Nalidixic acid < 4 1 4 1 MIC
29 Panel 1 Tetracycline = 2 0.5 2 1 MIC
29 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
29 Panel 2 Cefepime = 0.06 0.015 0.125 1 MIC
29 Panel 2 Ertapenem < 0.015 0.004 0.016 1 MIC
29 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
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29 Panel 2 Meropenem = 0.03 0.008 0.06 1 MIC
30 Panel 1 Ampicillin = 4 2 8 1 MIC
30 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
30 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
30 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
30 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
30 Panel 1 Colistin <= 1 0.25 2 1 MIC
30 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
30 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
30 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
30 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
30 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
30 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
30 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
30 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
30 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
30 Panel 2 Cefoxitin = 4 2 8 1 MIC
30 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
30 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
30 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
30 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
32 Panel 1 Ampicillin = 4 2 8 1 MIC
32 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
32 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
32 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
32 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
32 Panel 1 Colistin = 2 0.25 2 1 MIC
32 Panel 1 Gentamicin = 1 0.25 1 1 MIC
32 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
32 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
32 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
32 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
32 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
32 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
32 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
32 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
32 Panel 2 Cefoxitin = 2 2 8 1 MIC
32 Panel 2 Ceftazidime = 0.5 0.06 0.5 1 MIC
32 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
32 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
32 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
33 Panel 1 Ampicillin = 4 2 8 1 MIC
33 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
33 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
33 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
33 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
33 Panel 1 Colistin <= 1 0.25 2 1 MIC
33 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
33 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
33 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
33 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
33 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
33 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
33 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
33 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
33 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
33 Panel 2 Cefoxitin = 2 2 8 1 MIC
33 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
33 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
33 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
33 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
34 Panel 1 Ampicillin = 4 2 8 1 MIC
34 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
34 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
34 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
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34 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
34 Panel 1 Colistin <= 1 0.25 2 1 MIC
34 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
34 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
34 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
34 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
34 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
34 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
34 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
34 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
34 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
34 Panel 2 Cefoxitin = 4 2 8 1 MIC
34 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
34 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
34 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
34 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
36 Panel 1 Ampicillin = 4 2 8 1 MIC
36 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
36 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
36 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
36 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
36 Panel 1 Colistin <= 1 0.25 2 1 MIC
36 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
36 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
36 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
36 Panel 1 Sulfisoxazole <= 8 8 32 1 MIC
36 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
36 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
36 Panel 1 Trimethoprim <= 0.25 0.5 2 0 MIC
36 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
36 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
36 Panel 2 Cefoxitin = 4 2 8 1 MIC
36 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
36 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
36 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
36 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
37 Panel 1 Ampicillin = 4 2 8 1 AGA
37 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 AGA
37 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 AGA
37 Panel 1 Chloramphenicol <= 8 2 8 1 AGA
37 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 AGA
37 Panel 1 Colistin <= 1 0.25 2 1 AGA
37 Panel 1 Gentamicin <= 0.5 0.25 1 1 AGA
37 Panel 1 Meropenem <= 0.03 0.008 0.06 1 AGA
37 Panel 1 Nalidixic acid <= 4 1 4 1 AGA
37 Panel 1 Tetracycline <= 2 0.5 2 1 AGA
37 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 AGA
37 Panel 1 Trimethoprim = 0.5 0.5 2 1 AGA
37 Panel 2 Cefepime = 0.125 0.015 0.125 1 AGA
37 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 AGA
37 Panel 2 Cefoxitin = 4 2 8 1 AGA
37 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 AGA
37 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 AGA
37 Panel 2 Imipenem <= 0.125 0.06 0.25 1 AGA
37 Panel 2 Meropenem <= 0.03 0.008 0.06 1 AGA
38 Panel 1 Ampicillin = 4 2 8 1 MIC
38 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
38 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
38 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
38 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
38 Panel 1 Colistin = 1 0.25 2 1 MIC
38 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
38 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
38 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
38 Panel 1 Sulfisoxazole = 64 8 32 0 MIC
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38 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
38 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
38 Panel 1 Trimethoprim <= 0.25 0.5 2 0 MIC
38 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
38 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
38 Panel 2 Cefoxitin = 2 2 8 1 MIC
38 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
38 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
38 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
38 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
39 Panel 1 Ampicillin = 4 2 8 1 MIC
39 Panel 1 Cefotaxime = 0.06 0.03 0.125 1 MIC
39 Panel 1 Ceftazidime = 0.5 0.06 0.5 1 MIC
39 Panel 1 Chloramphenicol = 4 2 8 1 MIC
39 Panel 1 Ciprofloxacin = 0.016 0.004 0.016 1 MIC
39 Panel 1 Colistin <= 0.5 0.25 2 1 MIC
39 Panel 1 Gentamicin = 0.5 0.25 1 1 MIC
39 Panel 1 Nalidixic acid = 2 1 4 1 MIC
39 Panel 1 Tetracycline <= 1 0.5 2 1 MIC
39 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
40 Panel 1 Ampicillin = 4 2 8 1 MIC
40 Panel 1 Cefotaxime = 0.12 0.03 0.125 1 MIC
40 Panel 1 Ceftazidime = 0.5 0.06 0.5 1 MIC
40 Panel 1 Chloramphenicol = 8 2 8 1 MIC
40 Panel 1 Ciprofloxacin = 0.015 0.004 0.016 1 MIC
40 Panel 1 Colistin = 1 0.25 2 1 MIC
40 Panel 1 Gentamicin = 0.5 0.25 1 1 MIC
40 Panel 1 Meropenem = 0.03 0.008 0.06 1 MIC
40 Panel 1 Nalidixic acid = 4 1 4 1 MIC
40 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
40 Panel 1 Tetracycline = 2 0.5 2 1 MIC
40 Panel 1 Tigecycline = 0.25 0.03 0.25 1 MIC
40 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
40 Panel 2 Cefepime = 0.12 0.015 0.125 1 MIC
40 Panel 2 Cefotaxime = 0.12 0.03 0.125 1 MIC
40 Panel 2 Cefoxitin = 4 2 8 1 MIC
40 Panel 2 Ceftazidime = 0.5 0.06 0.5 1 MIC
40 Panel 2 Ertapenem = 0.015 0.004 0.016 1 MIC
40 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
40 Panel 2 Meropenem = 0.06 0.008 0.06 1 MIC
41 Panel 1 Ampicillin = 2 2 8 1 MIC
41 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
41 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
41 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
41 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
41 Panel 1 Colistin <= 1 0.25 2 1 MIC
41 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
41 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
41 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
41 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
41 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
41 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
41 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
41 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
41 Panel 2 Cefoxitin = 1 2 8 0 MIC
41 Panel 2 Ceftazidime = 0.5 0.06 0.5 1 MIC
41 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
41 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
41 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
42 Panel 1 Ampicillin = 4 2 8 1 MIC
42 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
42 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
42 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
42 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
42 Panel 1 Colistin <= 1 0.25 2 1 MIC
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42 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
42 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
42 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
42 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
42 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
42 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
42 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
45 Panel 1 Ampicillin = 4 2 8 1 MIC
45 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
45 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
45 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
45 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
45 Panel 1 Colistin <= 1 0.25 2 1 MIC
45 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
45 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
45 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
45 Panel 1 Sulfisoxazole = 64 8 32 0 MIC
45 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
45 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
45 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
45 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
45 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
45 Panel 2 Cefoxitin = 4 2 8 1 MIC
45 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
45 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
45 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
45 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
56 Panel 1 Ampicillin = 4 2 8 1 MIC
56 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
56 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
56 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
56 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
56 Panel 1 Colistin <= 1 0.25 2 1 MIC
56 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
56 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
56 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
56 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
56 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
56 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
56 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
56 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
56 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
56 Panel 2 Cefoxitin = 4 2 8 1 MIC
56 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
56 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
56 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
56 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
57 Panel 1 Ampicillin > 64 2 8 0 MIC
57 Panel 1 Cefotaxime = 8 0.03 0.125 0 MIC
57 Panel 1 Ceftazidime = 4 0.06 0.5 0 MIC
57 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
57 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
57 Panel 1 Colistin <= 1 0.25 2 1 MIC
57 Panel 1 Gentamicin = 1 0.25 1 1 MIC
57 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
57 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
57 Panel 1 Sulfisoxazole = 32 8 32 1 MIC
57 Panel 1 Tetracycline <= 32 0.5 2 1 MIC
57 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
57 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
57 Panel 2 Cefepime = 4 0.015 0.125 0 MIC
57 Panel 2 Cefotaxime = 2 0.03 0.125 0 MIC
57 Panel 2 Cefoxitin > 64 2 8 0 MIC
57 Panel 2 Ceftazidime = 4 0.06 0.5 0 MIC
57 Panel 2 Ertapenem = 0.03 0.004 0.016 0 MIC
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57 Panel 2 Imipenem <= 0.5 0.06 0.25 1 MIC
57 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
58 Panel 1 Ampicillin = 4 2 8 1 MIC
58 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
58 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
58 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
58 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
58 Panel 1 Colistin <= 1 0.25 2 1 MIC
58 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
58 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
58 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
58 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
58 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
58 Panel 1 Trimethoprim = 0.5 0.5 2 1 MIC
58 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
58 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
58 Panel 2 Cefoxitin = 2 2 8 1 MIC
58 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
58 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
58 Panel 2 Imipenem = 0.25 0.06 0.25 1 MIC
58 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
59 Panel 1 Ampicillin = 8 2 8 1 MIC
59 Panel 1 Cefotaxime <= 0.25 0.03 0.125 1 MIC
59 Panel 1 Ceftazidime <= 0.5 0.06 0.5 1 MIC
59 Panel 1 Chloramphenicol <= 8 2 8 1 MIC
59 Panel 1 Ciprofloxacin <= 0.015 0.004 0.016 1 MIC
59 Panel 1 Colistin <= 1 0.25 2 1 MIC
59 Panel 1 Gentamicin <= 0.5 0.25 1 1 MIC
59 Panel 1 Meropenem <= 0.03 0.008 0.06 1 MIC
59 Panel 1 Nalidixic acid <= 4 1 4 1 MIC
59 Panel 1 Sulfisoxazole = 16 8 32 1 MIC
59 Panel 1 Tetracycline <= 2 0.5 2 1 MIC
59 Panel 1 Tigecycline <= 0.25 0.03 0.25 1 MIC
59 Panel 1 Trimethoprim = 1 0.5 2 1 MIC
59 Panel 2 Cefepime <= 0.06 0.015 0.125 1 MIC
59 Panel 2 Cefotaxime <= 0.25 0.03 0.125 1 MIC
59 Panel 2 Cefoxitin = 2 2 8 1 MIC
59 Panel 2 Ceftazidime <= 0.25 0.06 0.5 1 MIC
59 Panel 2 Ertapenem <= 0.015 0.004 0.016 1 MIC
59 Panel 2 Imipenem <= 0.12 0.06 0.25 1 MIC
59 Panel 2 Meropenem <= 0.03 0.008 0.06 1 MIC
MIC: Microbroth dilution
AGA: Agar dilution
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Lab no. Antimicrobial Operator Value Low limit High limit Mark Method 36-37ºC/48h 42ºC/24h
1 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
1 Erythromycin = 2 0.5 2 1 MIC X
1 Gentamicin = 0.5 0.5 2 1 MIC X
1 Nalidixic acid = 8 4 16 1 MIC X
1 Tetracycline = 4 0.25 2 0 MIC X
2 Ciprofloxacin = 0.12 0.06 0.25 1 MIC X
2 Erythromycin = 1 0.5 2 1 MIC X
2 Gentamicin <= 0.12 0.5 2 0 MIC X
2 Nalidixic acid = 4 4 16 1 MIC X
2 Tetracycline = 1 0.25 2 1 MIC X
4 Ciprofloxacin = 0.12 0.06 0.25 1 MIC X
4 Erythromycin = 1 0.5 2 1 MIC X
4 Nalidixic acid = 4 4 16 1 MIC X
4 Tetracycline = 0.5 0.25 2 1 MIC X
6 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
6 Erythromycin <= 1 0.25 2 1 MIC X
6 Gentamicin = 1 0.25 2 1 MIC X
6 Nalidixic acid = 8 4 16 1 MIC X
6 Tetracycline <= 0.5 0.25 1 1 MIC X
9 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
9 Erythromycin = 1 0.5 2 1 MIC X
9 Gentamicin = 1 0.5 2 1 MIC X
9 Nalidixic acid = 8 4 16 1 MIC X
9 Tetracycline <= 0.5 0.25 2 1 MIC X
11 Ciprofloxacin = 0.12 0.06 0.25 1 MIC X
11 Erythromycin <= 0.5 0.5 2 1 MIC X
11 Gentamicin = 1 0.5 2 1 MIC X
11 Nalidixic acid = 8 4 16 1 MIC X
11 Tetracycline = 0.25 0.25 2 1 MIC X
12 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
12 Erythromycin <= 1 0.5 2 1 MIC X
12 Gentamicin = 1 0.5 2 1 MIC X
12 Nalidixic acid = 8 4 16 1 MIC X
12 Tetracycline = 1 0.25 2 1 MIC X
14 Ciprofloxacin <= 0.125 0.03 0.125 1 MIC X
14 Erythromycin <= 1 0.25 2 1 MIC X
14 Gentamicin = 0.5 0.25 2 1 MIC X
14 Nalidixic acid = 4 4 16 1 MIC X
14 Tetracycline <= 0.5 0.25 1 1 MIC X
17 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
17 Erythromycin <= 1 0.5 2 1 MIC X
17 Gentamicin = 1 0.5 2 1 MIC X
17 Nalidixic acid = 8 4 16 1 MIC X
17 Tetracycline = 1 0.25 2 1 MIC X
18 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
18 Erythromycin <= 1 0.25 2 1 MIC X
18 Gentamicin = 1 0.25 2 1 MIC X
18 Nalidixic acid = 4 4 16 1 MIC X
18 Tetracycline = 1 0.25 1 1 MIC X
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19 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
19 Erythromycin = 1 0.25 2 1 MIC X
19 Gentamicin = 2 0.25 2 1 MIC X
19 Nalidixic acid = 8 4 16 1 MIC X
19 Tetracycline = 2 0.25 1 0 MIC X
20 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
20 Erythromycin <= 1 0.25 2 1 MIC X
20 Gentamicin = 1 0.25 2 1 MIC X
20 Nalidixic acid = 4 4 16 1 MIC X
20 Tetracycline = 4 0.25 1 0 MIC X
21 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
21 Erythromycin < 1 0.25 2 1 MIC X
21 Gentamicin = 0.25 0.25 2 1 MIC X
21 Nalidixic acid = 4 4 16 1 MIC X
21 Tetracycline = 0.5 0.25 1 1 MIC X
22 Ciprofloxacin < 0.06 0.03 0.125 1 MIC X
22 Erythromycin < 1 0.25 2 1 MIC X
22 Nalidixic acid = 4 4 16 1 MIC X
22 Tetracycline = 1 0.25 1 1 MIC X
23 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
23 Erythromycin < 0.5 0.25 2 1 MIC X
23 Gentamicin = 1 0.25 2 1 MIC X
23 Nalidixic acid = 4 4 16 1 MIC X
23 Tetracycline = 0.5 0.25 1 1 MIC X
25 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
25 Erythromycin = 2 0.5 2 1 MIC X
25 Gentamicin = 0.25 0.5 2 0 MIC X
25 Nalidixic acid = 8 4 16 1 MIC X
25 Tetracycline = 2 0.25 2 1 MIC X
26 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
26 Erythromycin <= 1 0.5 2 1 MIC X
26 Gentamicin = 0.5 0.5 2 1 MIC X
26 Nalidixic acid = 8 4 16 1 MIC X
26 Tetracycline = 1 0.25 2 1 MIC X
29 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
29 Erythromycin < 1 0.5 2 1 MIC X
29 Gentamicin = 1 0.5 2 1 MIC X
29 Nalidixic acid = 16 4 16 1 MIC X
29 Tetracycline = 2 0.25 2 1 MIC X
30 Ciprofloxacin = 0.5 0.06 0.25 0 MIC X
30 Erythromycin <= 1 0.5 2 1 MIC X
30 Nalidixic acid = 4 4 16 1 MIC X
30 Tetracycline <= 0.5 0.25 2 1 MIC X
32 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
32 Erythromycin <= 1 0.5 2 1 MIC X
32 Gentamicin = 1 0.5 2 1 MIC X
32 Nalidixic acid = 8 4 16 1 MIC X
32 Tetracycline = 1 0.25 2 1 MIC X
33 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
33 Erythromycin = 2 0.5 2 1 MIC X
33 Gentamicin = 0.5 0.5 2 1 MIC X
33 Nalidixic acid = 8 4 16 1 MIC X
33 Tetracycline = 1 0.25 2 1 MIC X
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34 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
34 Erythromycin <= 1 0.5 2 1 MIC X
34 Gentamicin = 0.5 0.5 2 1 MIC X
34 Nalidixic acid = 4 4 16 1 MIC X
34 Tetracycline = 1 0.25 2 1 MIC X
36 Ciprofloxacin = 0.5 0.06 0.25 0 MIC X
36 Erythromycin <= 0.5 0.5 2 1 MIC X
36 Gentamicin = 1 0.5 2 1 MIC X
36 Nalidixic acid = 16 4 16 1 MIC X
36 Tetracycline = 2 0.25 2 1 MIC X
37 Ciprofloxacin = 0.25 0.12 1 1 AGA X
37 Erythromycin <= 1 1 8 1 AGA X
37 Gentamicin = 1 0.5 2 1 AGA X
39 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
39 Erythromycin = 0.5 0.25 2 1 MIC X
39 Gentamicin = 0.5 0.25 2 1 MIC X
39 Nalidixic acid <= 4 4 16 1 MIC X
39 Tetracycline = 1 0.25 1 1 MIC X
40 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
40 Erythromycin = 1 0.25 2 1 MIC X
40 Gentamicin = 0.25 0.25 2 1 MIC X
40 Nalidixic acid = 8 4 16 1 MIC X
40 Tetracycline = 1 0.25 1 1 MIC X
41 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
41 Erythromycin <= 1 0.25 2 1 MIC X
41 Gentamicin = 0.25 0.25 2 1 MIC X
41 Nalidixic acid = 4 4 16 1 MIC X
41 Tetracycline <= 0.5 0.25 1 1 MIC X
42 Ciprofloxacin = 0.25 0.06 0.25 1 MIC X
42 Erythromycin = 2 0.5 2 1 MIC X
42 Gentamicin = 0.5 0.5 2 1 MIC X
42 Nalidixic acid = 16 4 16 1 MIC X
42 Tetracycline = 2 0.25 2 1 MIC X
45 Ciprofloxacin <= 0.12 0.06 0.25 1 MIC X
45 Erythromycin <= 1 0.5 2 1 MIC X
45 Gentamicin = 1 0.5 2 1 MIC X
45 Nalidixic acid = 8 4 16 1 MIC X
45 Tetracycline = 2 0.25 2 1 MIC X
56 Ciprofloxacin = 0.12 0.03 0.125 1 MIC X
56 Erythromycin <= 0.5 0.25 2 1 MIC X
56 Gentamicin = 1 0.25 2 1 MIC X
56 Nalidixic acid = 8 4 16 1 MIC X
56 Tetracycline = 0.5 0.25 1 1 MIC X
58 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
58 Erythromycin = 2 0.25 2 1 MIC X
58 Gentamicin = 1 0.25 2 1 MIC X
58 Nalidixic acid = 4 4 16 1 MIC X
58 Tetracycline = 1 0.25 1 1 MIC X
59 Ciprofloxacin <= 0.12 0.03 0.125 1 MIC X
59 Erythromycin <= 1 0.25 2 1 MIC X
59 Gentamicin = 0.5 0.25 2 1 MIC X
59 Nalidixic acid = 8 4 16 1 MIC X
59 Tetracycline = 2 0.25 1 0 MIC X
MIC: microbroth dilution
AGA: agar dilution
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Salmonella - expected and obtained interpretation
Antimicrobial Strain Panel Expected % R % S No. correct No. incorrect
Ampicillin AMP EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 R 100 0 35 0
EURL S-9.3 Panel 1 R 100 0 35 0
EURL S-9.4 Panel 1 R 100 0 35 0
EURL S-9.5 Panel 1 R 100 0 35 0
EURL S-9.6 Panel 1 R 100 0 35 0
EURL S-9.7 Panel 1 R 100 0 35 0
EURL S-9.8 Panel 1 S 0 100 35 0
Cefotaxime FOT EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 S 0 100 35 0
EURL S-9.3 Panel 1 R 100 0 35 0
EURL S-9.3 Panel 2 R 100 0 35 0
EURL S-9.4 Panel 1 R 100 0 35 0
EURL S-9.4 Panel 2 R 97 3 33 1
EURL S-9.5 Panel 1 R 100 0 35 0
EURL S-9.5 Panel 2 R 100 0 35 0
EURL S-9.6 Panel 1 S 6 94 33 2
EURL S-9.6 Panel 2 S 3 97 31 1
EURL S-9.7 Panel 1 S 0 100 35 0
EURL S-9.8 Panel 1 S 0 100 35 0
Cefoxitin FOX EURL S-9.3 Panel 2 R 100 0 35 0
EURL S-9.4 Panel 2 S 0 100 34 0
EURL S-9.5 Panel 2 R 100 0 35 0
EURL S-9.6 Panel 2 S 9 91 29 3
Ceftazidime TAZ EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 S 0 100 35 0
EURL S-9.3 Panel 1 R 100 0 35 0
EURL S-9.3 Panel 2 R 100 0 35 0
EURL S-9.4 Panel 1 S 6 94 33 2
EURL S-9.4 Panel 2 S 9 91 31 3
EURL S-9.5 Panel 1 R 100 0 35 0
EURL S-9.5 Panel 2 R 100 0 35 0
EURL S-9.6 Panel 1 S 0 100 35 0
EURL S-9.6 Panel 2 S 3 97 31 1
EURL S-9.7 Panel 1 S 3 97 34 1
EURL S-9.8 Panel 1 S 0 100 35 0
Chloramphenicol CHL EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 S 0 100 35 0
EURL S-9.3 Panel 1 R 100 0 35 0
EURL S-9.4 Panel 1 S 3 97 34 1
EURL S-9.5 Panel 1 S 0 100 35 0
EURL S-9.6 Panel 1 S 0 100 35 0
EURL S-9.7 Panel 1 S 0 100 35 0
EURL S-9.8 Panel 1 S 0 100 35 0
Ciprofloxacin CIP EURL S-9.1 Panel 1 S 3 97 34 1
EURL S-9.2 Panel 1 R 100 0 35 0
EURL S-9.3 Panel 1 S 3 97 34 1
EURL S-9.4 Panel 1 R 100 0 35 0
EURL S-9.5 Panel 1 R 97 3 34 1
EURL S-9.6 Panel 1 R 100 0 35 0
EURL S-9.7 Panel 1 S 0 100 35 0
EURL S-9.8 Panel 1 S 3 97 34 1
Colistin COL EURL S-9.1 Panel 1 R 88 12 30 4
EURL S-9.2 Panel 1 S 3 97 34 1
EURL S-9.3 Panel 1 S 0 100 35 0
EURL S-9.4 Panel 1 S 0 100 35 0
EURL S-9.5 Panel 1 S 0 100 35 0
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EURL S-9.6 Panel 1 S 0 100 35 0
EURL S-9.7 Panel 1 S 0 100 35 0
EURL S-9.8* Panel 1 S 38 63 20 12
Ertapenem ETP EURL S-9.3 Panel 2 S 0 100 34 0
EURL S-9.4 Panel 2 S 3 97 32 1
EURL S-9.5 Panel 2 R 94 6 32 2
EURL S-9.6 Panel 2 R 97 3 30 1
Gentamicin GEN EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 R 100 0 35 0
EURL S-9.3 Panel 1 S 3 97 34 1
EURL S-9.4 Panel 1 S 0 100 35 0
EURL S-9.5 Panel 1 R 100 0 35 0
EURL S-9.6 Panel 1 S 0 100 35 0
EURL S-9.7 Panel 1 S 0 100 35 0
EURL S-9.8 Panel 1 S 0 100 35 0
Imipenem IMI EURL S-9.3 Panel 2 S 0 100 35 0
EURL S-9.4 Panel 2 S 3 97 33 1
EURL S-9.5 Panel 2 R 77 23 27 8
EURL S-9.6 Panel 2 S 19 81 25 6
Meropenem MER EURL S-9.1 Panel 1 S 0 100 34 0
EURL S-9.2 Panel 1 S 0 100 34 0
EURL S-9.3 Panel 1 S 0 100 34 0
EURL S-9.3 Panel 2 S 0 100 35 0
EURL S-9.4 Panel 1 S 0 100 34 0
EURL S-9.4 Panel 2 S 3 97 33 1
EURL S-9.5 Panel 1 R 64 36 21 12
EURL S-9.5 Panel 2 R 68 32 23 11
EURL S-9.6 Panel 1 R 82 18 28 6
EURL S-9.6 Panel 2 R 74 26 23 8
EURL S-9.7 Panel 1 S 0 100 34 0
EURL S-9.8 Panel 1 S 0 100 34 0
Nalidixic acid NAL EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 R 79 21 27 7
EURL S-9.3 Panel 1 S 0 100 35 0
EURL S-9.4 Panel 1 R 97 3 34 1
EURL S-9.5 Panel 1 R 100 0 35 0
EURL S-9.6 Panel 1 R 100 0 35 0
EURL S-9.7 Panel 1 S 0 100 35 0
EURL S-9.8 Panel 1 S 0 100 35 0
Sulfamethoxazole SMX EURL S-9.1 Panel 1 S 0 100 34 0
EURL S-9.2 Panel 1 S 3 97 33 1
EURL S-9.3 Panel 1 R 97 3 33 1
EURL S-9.4 Panel 1 S 3 97 33 1
EURL S-9.5 Panel 1 R 100 0 34 0
EURL S-9.6 Panel 1 S 0 100 34 0
EURL S-9.7 Panel 1 R 100 0 34 0
EURL S-9.8 Panel 1 S 0 100 34 0
Tetracycline TET EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 S 0 100 35 0
EURL S-9.3 Panel 1 R 100 0 35 0
EURL S-9.4 Panel 1 R 100 0 35 0
EURL S-9.5 Panel 1 R 100 0 35 0
EURL S-9.6 Panel 1 S 0 100 35 0
EURL S-9.7 Panel 1 R 100 0 35 0
EURL S-9.8 Panel 1 S 0 100 35 0
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Tigecycline TGC EURL S-9.1 Panel 1 S 0 100 31 0
EURL S-9.2 Panel 1 S 0 100 31 0
EURL S-9.3 Panel 1 S 0 100 32 0
EURL S-9.4 Panel 1 S 0 100 31 0
EURL S-9.5 Panel 1 S 0 100 30 0
EURL S-9.6 Panel 1 S 0 100 30 0
EURL S-9.7 Panel 1 R 71 29 20 8
EURL S-9.8 Panel 1 S 0 100 33 0
Trimethoprim TMP EURL S-9.1 Panel 1 S 0 100 35 0
EURL S-9.2 Panel 1 S 0 100 35 0
EURL S-9.3 Panel 1 S 6 94 33 2
EURL S-9.4 Panel 1 S 0 100 35 0
EURL S-9.5 Panel 1 S 0 100 35 0
EURL S-9.6 Panel 1 S 3 97 34 1
EURL S-9.7 Panel 1 R 100 0 35 0
EURL S-9.8 Panel 1 S 0 100 34 0
*Strain/antimicrobial-combination excluded from the evaluation
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Antimicrobial Strain Expected % R % S No. correct
No. 
incorrect
EURL C-9.1 R 97 3 31 1
EURL C-9.2 S 6 94 29 2
EURL C-9.3 R 97 3 30 1
EURL C-9.4 R 100 0 30 0
EURL C-9.5 S 6 94 29 2
EURL C-9.6 R 100 0 32 0
EURL C-9.7 R 93 7 28 2
EURL C-9.8 S 6 94 30 2
EURL C-9.1 S 3 97 31 1
EURL C-9.2 R 100 0 31 0
EURL C-9.3 S 13 87 27 4
EURL C-9.4 R 100 0 30 0
EURL C-9.5 S 6 94 29 2
EURL C-9.6 R 100 0 32 0
EURL C-9.7 S 10 90 27 3
EURL C-9.8 R 97 3 31 1
EURL C-9.1 S 0 100 32 0
EURL C-9.2 S 0 100 31 0
EURL C-9.3 S 0 100 31 0
EURL C-9.4 R 93 7 28 2
EURL C-9.5 S 3 97 30 1
EURL C-9.6 S 3 97 31 1
EURL C-9.7 S 0 100 30 0
EURL C-9.8 S 0 100 32 0
EURL C-9.1 R 100 0 32 0
EURL C-9.2 S 6 94 29 2
EURL C-9.3 R 97 3 30 1
EURL C-9.4 R 97 3 29 1
EURL C-9.5 S 6 94 29 2
EURL C-9.6 R 97 3 31 1
EURL C-9.7 S 10 90 27 3
EURL C-9.8 S 3 97 31 1
EURL C-9.1 S 3 97 30 1
EURL C-9.2 S 10 90 27 3
EURL C-9.3 R 100 0 30 0
EURL C-9.4 R 100 0 29 0
EURL C-9.5 S 7 93 28 2
EURL C-9.6 R 100 0 31 0
EURL C-9.7 S 10 90 26 3
EURL C-9.8 R 97 3 30 1
EURL C-9.1 R 100 0 32 0
EURL C-9.2 S 23 77 23 7
EURL C-9.3 R 97 3 30 1
EURL C-9.4 R 100 0 30 0
EURL C-9.5 S 6 94 29 2
EURL C-9.6* R 68 32 21 10
EURL C-9.7 S 3 97 29 1
EURL C-9.8 S 3 97 31 1
*Strain/antimicrobial-combination excluded from the evaluation
Ciprofloxacin, CIP
Tetracycline, TET
Streptomycin, STR
Nalidixic acid, NAL
Gentamicin, GEN
Erythromycin, ERY
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Lab no. Strain Panel Antimicrobial Obtained interpretation
Obtained 
value
Expected 
interpretation
Expected MIC / 
ESBL conclusion
1 EURL S-9.6 Panel 1 Cefotaxime FOT R 1 S = 0.5
1 EURL S-9.6 Panel 2 Cefoxitin FOX R 16 S 8
1 EURL S-9.6 Panel 2 Imipenem IMI R 2 S 1
2 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
2 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
2 EURL S-9.6 Panel 1 Meropenem MER S 0.12 R = 0.5
2 EURL S-9.6 Panel 2 Meropenem MER S 0.12 R = 0.5
4 EURL S-9.6 Panel 2 Meropenem MER S 0.12 R = 0.5
6 EURL S-9.6 Panel 2 Imipenem IMI R 2 S 1
9 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
11 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
12 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
12 EURL S-9.6 Panel 1 Meropenem MER S 0.12 R = 0.5
12 EURL S-9.6 Panel 2 Meropenem MER S 0.12 R = 0.5
12 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
13 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
13 EURL S-9.3 Panel 1 Trimethoprim TMP R >32 S <= 0.25
13 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
13 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
13 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
19 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
20 EURL S-9.5 Panel 1 Ciprofloxacin CIP S >8 R > 8
21 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
21 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
22 EURL S-9.6 Panel 1 Trimethoprim TMP R 4 S <= 0.25
22 EURL S-9.6 Panel 2 Cefoxitin FOX R 16 S 8
23 EURL S-9.1 Panel 1 Colistin COL S 2 R 8
23 EURL S-9.4 ESBL test conclusion Unusual phenotype Presumptive ESBL
23 EURL S-9.5 Panel 1 Meropenem MER S <0.03 R 1
23 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
23 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
23 EURL S-9.5 ESBL test conclusion Presumptive pAmpC Presumptive carbapenemase
23 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
26 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
26 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
26 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
26 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
26 EURL S-9.5 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
26 EURL S-9.6 Panel 2 Meropenem MER S 0.12 R = 0.5
26 EURL S-9.6 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
26 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
29 EURL S-9.1 Panel 1 Colistin COL S 2 R 8
29 EURL S-9.4 ESBL test conclusion No ESBL, AmpC- or carba Presumptive ESBL
29 EURL S-9.5 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
30 EURL S-9.5 Panel 1 Meropenem MER S 0.125 R 1
30 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
30 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
30 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
32 EURL S-9.3 ESBL test conclusion Presumptive ESBL + pAmpC Presumptive pAmpC
32 EURL S-9.6 Panel 2 Meropenem MER S <=0.12 R = 0.5
33 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
33 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
33 EURL S-9.6 Panel 1 Meropenem MER S 0.12 R = 0.5
33 EURL S-9.6 Panel 2 Meropenem MER S 0.12 R = 0.5
33 EURL S-9.6 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
33 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
34 EURL S-9.4 Panel 1 Nalidixic acid NAL S <=4 R > 128
36 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
36 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
36 EURL S-9.5 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
36 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
37 EURL S-9.5 Panel 1 Meropenem MER S 0.06 R 1
37 EURL S-9.5 Panel 2 Meropenem MER S 0.125 R 1
37 EURL S-9.6 Panel 1 Meropenem MER S 0.125 R = 0.5
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37 EURL S-9.6 ESBL test conclusion No ESBL, AmpC- or carba Presumptive carbapenemase
38 EURL S-9.6 Panel 2 Imipenem IMI R 2 S 1
39 EURL S-9.1 Panel 1 Colistin COL S 2 R 8
39 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
39 EURL S-9.4 ESBL test conclusion Unusual phenotype Presumptive ESBL
39 EURL S-9.5 Panel 2 Meropenem MER S <=1 R 1
39 EURL S-9.5 ESBL test conclusion Presumptive pAmpC Presumptive carbapenemase
39 EURL S-9.6 Panel 2 Meropenem MER S <=1 R = 0.5
39 EURL S-9.6 ESBL test conclusion No ESBL, AmpC- or carba Presumptive carbapenemase
39 EURL S-9.7 ESBL test conclusion Presumptive pAmpC No ESBL, AmpC- or carba
40 EURL S-9.1 Panel 1 Colistin COL S 2 R 8
40 EURL S-9.3 Panel 1 Sulfamethoxazole SMX S 128 R > 1024
40 EURL S-9.6 Panel 2 Cefoxitin FOX R 16 S 8
41 EURL S-9.3 ESBL test conclusion Presumptive ESBL + pAmpC Presumptive pAmpC
41 EURL S-9.4 Panel 1 Ceftazidime TAZ R 1 S 1
41 EURL S-9.4 Panel 2 Ceftazidime TAZ R 1 S 1
41 EURL S-9.6 Panel 1 Cefotaxime FOT R 0.5 S = 0.5
41 EURL S-9.6 Panel 2 Cefotaxime FOT R 0.5 S = 0.5
41 EURL S-9.6 Panel 2 Imipenem IMI R 2 S 1
41 EURL S-9.7 Panel 1 Ceftazidime TAZ R 1 S <= 0.5
41 EURL S-9.7 ESBL test conclusion Unusual phenotype No ESBL, AmpC- or carba
42 EURL S-9.2 Panel 1 Nalidixic acid NAL S 16 R 32
42 EURL S-9.3 ESBL test conclusion Presumptive ESBL + pAmpC Presumptive pAmpC
42 EURL S-9.6 Panel 1 Meropenem MER S 0.12 R = 0.5
42 EURL S-9.6 Panel 2 Meropenem MER S 0.12 R = 0.5
42 EURL S-9.6 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
45 EURL S-9.6 Panel 2 Imipenem IMI R 2 S 1
45 EURL S-9.7 Panel 1 Tigecycline TGC S 1 R 2
57 EURL S-9.2 Panel 1 Sulfamethoxazole SMX R 128 S 128
57 EURL S-9.3 Panel 1 Trimethoprim TMP R 32 S <= 0.25
57 EURL S-9.4 Panel 2 Cefotaxime FOT S 8 R 16
57 EURL S-9.4 Panel 2 Ceftazidime TAZ R 0.5 S 1
57 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
57 EURL S-9.5 Panel 2 Ertapenem ETP S 0.06 R = 0.5
57 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
57 EURL S-9.5 Panel 2 Meropenem MER S <=1 R 1
57 EURL S-9.5 ESBL test conclusion Presumptive pAmpC Presumptive carbapenemase
57 EURL S-9.6 Panel 1 Meropenem MER S <=0.25 R = 0.5
57 EURL S-9.6 Panel 2 Ertapenem ETP S <=0.25 R = .25
58 EURL S-9.1 Panel 1 Ciprofloxacin CIP R 0.12 S = 0.03
58 EURL S-9.2 Panel 1 Colistin COL R 4 S <= 1
58 EURL S-9.3 Panel 1 Ciprofloxacin CIP R 0.25 S = 0.03
58 EURL S-9.3 Panel 1 Gentamicin GEN R >32 S <= 0.5
58 EURL S-9.4 Panel 1 Ceftazidime TAZ R 8 S 1
58 EURL S-9.4 Panel 1 Chloramphenicol CHL R 128 S <= 8
58 EURL S-9.4 Panel 1 Sulfamethoxazole SMX R >1024 S 64
58 EURL S-9.4 Panel 2 Ceftazidime TAZ R 8 S 1
58 EURL S-9.5 Panel 1 Meropenem MER S 0.12 R 1
58 EURL S-9.5 Panel 2 Imipenem IMI S 1 R 4
58 EURL S-9.5 Panel 2 Meropenem MER S 0.12 R 1
58 EURL S-9.5 ESBL test conclusion Presumptive pAmpC Presumptive carbapenemase
58 EURL S-9.6 ESBL test conclusion Unusual phenotype Presumptive carbapenemase
58 EURL S-9.8 Panel 1 Ciprofloxacin CIP R 0.12 S <= 0.015
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1 EURL C-9.2 Tetracycline TET R 4 S 2
1 EURL C-9.7 Nalidixic acid NAL R >64 S 2
4 EURL C-9.3 Erythromycin ERY R 16 S 4
11 EURL C-9.6 Nalidixic acid NAL S 8 R 64
19 EURL C-9.7 Erythromycin ERY R >32 S <= 1
19 EURL C-9.7 Nalidixic acid NAL R >64 S 2
19 EURL C-9.7 Streptomycin STR R >16 S = 0.5
19 EURL C-9.8 Ciprofloxacin CIP R >4 S <= 0.1
19 EURL C-9.8 Erythromycin ERY S <=0.5 R > 128
19 EURL C-9.8 Streptomycin STR S 4 R > 16
20 EURL C-9.2 Streptomycin STR R 8 S 1
29 EURL C-9.1 Erythromycin ERY R 32 S <= 1
29 EURL C-9.1 Streptomycin STR R >16 S = 0.5
29 EURL C-9.2 Ciprofloxacin CIP R 2 S = 0.3
29 EURL C-9.2 Nalidixic acid NAL R 32 S 8
29 EURL C-9.2 Streptomycin STR R >16 S 1
29 EURL C-9.2 Tetracycline TET R 4 S 2
29 EURL C-9.3 Erythromycin ERY R 32 S 4
29 EURL C-9.4 Gentamicin GEN S 0.5 R > 16
30 EURL C-9.2 Tetracycline TET R 4 S 2
34 EURL C-9.2 Tetracycline TET R 4 S 2
34 EURL C-9.3 Tetracycline TET S 2 R > 64
34 EURL C-9.7 Tetracycline TET R >64 S <= 0.5
36 EURL C-9.7 Ciprofloxacin CIP S 0.12 R 16
36 EURL C-9.7 Erythromycin ERY R >64 S <= 1
36 EURL C-9.7 Streptomycin STR R >64 S = 0.5
39 EURL C-9.1 Ciprofloxacin CIP S 4 R 8
39 EURL C-9.3 Nalidixic acid NAL S 16 R > 64
39 EURL C-9.4 Nalidixic acid NAL S 16 R > 64
40 EURL C-9.2 Ciprofloxacin CIP R 1 S = 0.3
40 EURL C-9.2 Nalidixic acid NAL R 64 S 8
40 EURL C-9.2 Streptomycin STR R 8 S 1
40 EURL C-9.2 Tetracycline TET R 64 S 2
40 EURL C-9.3 Ciprofloxacin CIP S 0.5 R > 16
40 EURL C-9.3 Erythromycin ERY R 32 S 4
40 EURL C-9.4 Gentamicin GEN S 0.25 R > 16
40 EURL C-9.5 Ciprofloxacin CIP R 64 S <= 0.1
40 EURL C-9.5 Erythromycin ERY R 64 S <= 1
40 EURL C-9.5 Nalidixic acid NAL R 64 S 4
40 EURL C-9.5 Streptomycin STR R 16 S 1
40 EURL C-9.5 Tetracycline TET R 64 S <= 0.5
40 EURL C-9.7 Nalidixic acid NAL R 32 S 2
40 EURL C-9.8 Ciprofloxacin CIP R 4 S <= 0.1
40 EURL C-9.8 Nalidixic acid NAL R 64 S 8
40 EURL C-9.8 Tetracycline TET R 64 S 1
41 EURL C-9.2 Tetracycline TET R 4 S 2
42 EURL C-9.2 Tetracycline TET R 4 S 2
42 EURL C-9.6 Gentamicin GEN R 1 S 1
42 EURL C-9.7 Ciprofloxacin CIP S <=0.06 R 16
42 EURL C-9.7 Erythromycin ERY R >32 S <= 1
42 EURL C-9.7 Streptomycin STR R >16 S = 0.5
58 EURL C-9.5 Ciprofloxacin CIP R 8 S <= 0.1
58 EURL C-9.5 Erythromycin ERY R >128 S <= 1
58 EURL C-9.5 Gentamicin GEN R >16 S = 0.3
58 EURL C-9.5 Nalidixic acid NAL R 32 S 4
58 EURL C-9.5 Streptomycin STR R >16 S 1
58 EURL C-9.5 Tetracycline TET R 32 S <= 0.5
59 EURL C-9.3 Erythromycin ERY R >128 S 4
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1 EURL-S9.3 CMY -2 Whole genome sequenced Zankari, E. et al, 2012 ‐ ‐
1 EURL-S9.4 CTX M-9 Whole genome sequenced Zankari, E. et al, 2012 ‐ ‐
1 EURL-S9.5 VIM -2 Whole genome sequenced Zankari, E. et al, 2012 ‐ ‐
1 EURL-S9.6 OXA -48 Whole genome sequenced Zankari, E. et al, 2012 ‐ ‐
4 EURL-S9.3 CMY -2 PCR (in‐house) Hasman et al. 2005 ‐ ‐
4 EURL-S9.4 OXA - X PCR (in‐house) Hasman et al. 2005 ‐ ‐
4 EURL-S9.4 SHV - X PCR (in‐house) Arlet et al. 1997 ‐ ‐
4 EURL-S9.4 CTX M-9 PCR (in‐house) Pagani et al. 2003 ‐ ‐
4 EURL-S9.4 TEM -1 PCR (in‐house) Olesen et al 2004 ‐ ‐
4 EURL-S9.5 CTX - X PCR (published) Pagani et al. 2003 ‐ ‐
4 EURL-S9.5 IMP - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.5 KPC - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.5 NDM - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.5 OXA - X PCR (published) Hasman et al. 2005 ‐ ‐
4 EURL-S9.5 OXA - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.5 SHV - X PCR (published) Arlet et al. 1997 ‐ ‐
4 EURL-S9.5 TEM -1 PCR (published) Olesen et al 2004 ‐ ‐
4 EURL-S9.5 VIM -2 PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.6 IMP - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.6 KPC - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.6 NDM - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.6 VIM - X PCR (published) Poirel et al. 2011 ‐ ‐
4 EURL-S9.6 OXA -48 PCR (published) Poirel et al. 2011 ‐ ‐
9 EURL-S9.3 CMY -2 PCR (published) JAC 2010;65;490‐495; ‐ ‐
9 EURL-S9.4 CTX M-9 PCR (published) JAC 2010;65;490‐495; ‐ ‐
9 EURL-S9.4 TEM -1 PCR (published) JAC 2010;65;490‐495; ‐ ‐
9 EURL-S9.5 TEM -1 PCR (published) JAC 2010;65;490‐495; ‐ ‐
9 EURL-S9.5 VIM -2 PCR (published) JAC 2010;65;490‐495; ‐ ‐
9 EURL-S9.6 OXA -48 PCR (published) JAC 2010;65;490‐495; ‐ ‐
17 EURL-S9.3 ACC - X PCR (published) Pérez‐Pérez et al. JCM 2002 ‐ ‐
17 EURL-S9.3 CTX - X PCR (published) Batchelor et al. AAC 2005 ‐ ‐
17 EURL-S9.3 DHA - X PCR (published) Pérez‐Pérez et al. JCM 2002 ‐ ‐
17 EURL-S9.3 FOX - X PCR (published) Pérez‐Pérez et al. JCM 2002 ‐ ‐
17 EURL-S9.3 MOX - X PCR (published) Pérez‐Pérez et al. JCM 2002 ‐ ‐
17 EURL-S9.3 SHV - X PCR (published) Weill et al. JCM 2004 ‐ ‐
17 EURL-S9.3 TEM - X PCR (published) Guerra et al. AAC 2001 ‐ ‐
17 EURL-S9.3 CMY -2 PCR (published) Zhao et al. AAC 2001 ‐ ‐
17 EURL-S9.4 ACC - X PCR (published) ‐ ‐ ‐
17 EURL-S9.4 DHA - X PCR (published) ‐ ‐ ‐
17 EURL-S9.4 FOX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.4 MOX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.4 SHV - X PCR (published) ‐ ‐ ‐
17 EURL-S9.4 TEM - X PCR (published) ‐ ‐ ‐
17 EURL-S9.4 CTX M-9 PCR (published) Paauw et al. EID 2006 ‐ ‐
Method Reference Primer 5 3 Primer 3 5Labno Strain Genetype
Gene 
number
Not 
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17 EURL-S9.5 ACC - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 CTX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 DHA - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 FOX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 IMP - X PCR (published) Dallene et al. JAC 2010 ‐ ‐
17 EURL-S9.5 KPC - X PCR (published) Dallene et al. JAC 2010 ‐ ‐
17 EURL-S9.5 MOX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 NDM - X PCR (published) Poirel et al. DMID 2011 ‐ ‐
17 EURL-S9.5 OXA -48 X PCR (published) Dallene et al. JAC 2010 ‐ ‐
17 EURL-S9.5 SHV - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 TEM - X PCR (published) ‐ ‐ ‐
17 EURL-S9.5 VIM -2 PCR (in‐house) see comments ‐ ‐
17 EURL-S9.6 ACC - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 CTX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 DHA - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 FOX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 IMP - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 KPC - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 MOX - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 NDM - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 PER - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 SHV - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 TEM - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 VIM - X PCR (published) ‐ ‐ ‐
17 EURL-S9.6 OXA -48 PCR (published) Aubert JB 2006 ‐ ‐
21 EURL-S9.3 CMY -2 PCR (published) Pérez‐Pérez & Hanson, 2002 ‐ ‐
21 EURL-S9.4 CTX - PCR (published) Woodford et al., 2006 ‐ ‐
21 EURL-S9.5 VIM - PCR (published) Poirel et al., 2011 ‐ ‐
21 EURL-S9.6 OXA -48 PCR (published) Poirel et al., 2011 ‐ ‐
25 EURL-S9.3 CMY -2 PCR (published) Dierikx, Vet Mic, 2010 ‐ ‐
25 EURL-S9.4 CTX M-9 PCR (published) Paauw A, EID, 2006 ‐ ‐
25 EURL-S9.4 TEM -1 PCR (published) Dierikx, Vet Mic, 2010 ‐ ‐
25 EURL-S9.5 TEM -1 PCR (published) Dierikx, Vet MIc, 2010 ‐ ‐
25 EURL-S9.5 VIM -2 PCR (published) Ellington, JAC, 2007 ‐ ‐
25 EURL-S9.6 OXA -48 PCR (published) Poirel, AAC., 2004 ‐ ‐
26 EURL-S9.3 CMY -2 PCR (published) JAC 2005, 56, 115 GCACTTAGCCACCTATACGGCAG GCTTTTCAAGAATGCGCCAGG
26 EURL-S9.4 SHV - X PCR (published) JCM, 2010, 48, 460 CAAAACGCCGGGTTATTC TTAGCGTTGCCAGTGCT
26 EURL-S9.4 CTX - PCR (published) JCM, 2003, 41, 460 ATGTGCAGYACCAGTAARGTKATGGC TGGGTRAARTARGTSACCAGAAYCAGCGG
26 EURL-S9.4 TEM - PCR (published) JCM, 2010, 48, 460 TGAGTATTCAACATTTCCGTGT TTACCAATGCTTAATCAGTGA
26 EURL-S9.5 CMY -2 X PCR (published) JAC, 2005, 56, 115 GCACTTAGCCACCTATACGGCAG GCTTTTCAAGAATGCGCCAGG
32 EURL-S9.3 ACC - X PCR (published) Hasman et al. 2005 ‐ ‐
32 EURL-S9.3 ACT - X PCR (published) Voets et al. 2011 ‐ ‐
32 EURL-S9.3 CTX - X PCR (published) PediaInfectDisJ28:814‐818.2009 ‐ ‐
32 EURL-S9.3 DHA - X PCR (published) Gonzalez‐Sanz et al.2009 ‐ ‐
32 EURL-S9.3 FOX - X PCR (published) ANTIMAGENTCHEMOTHe2006.618–624 ‐ ‐
32 EURL-S9.3 IMP - X PCR (published) L. Poirel et al 2011 ‐ ‐
32 EURL-S9.3 KPC - X PCR (published) Dallanne et al 2010 ‐ ‐
32 EURL-S9.3 MOX - X PCR (published) Voets et al. 2011 ‐ ‐
32 EURL-S9.3 NDM - X PCR (published) L. Poirel et al 2011 ‐ ‐
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32 EURL-S9.3 OXA -48 X PCR (published) Voets et al 2011 ‐ ‐
32 EURL-S9.3 OXA -30 X PCR (published) JAntimChemoth2009641181–1186; ‐ ‐
32 EURL-S9.3 OXA -10 X PCR (published) Voets et al. 2011 ‐ ‐
32 EURL-S9.3 SHV - X PCR (published) FEMSMicrobiLett.1997152:163‐7 ‐ ‐
32 EURL-S9.3 TEM - X PCR (published) AntimicrAgentsChemoth2009 ‐ ‐
32 EURL-S9.3 VEB - X PCR (published) Dallanne et al 2010 ‐ ‐
32 EURL-S9.3 VIM - X PCR (published) Dallanne et al 2010 ‐ ‐
32 EURL-S9.3 CMY -2 PCR (published) JAntimChemother200656:115‐121. ‐ ‐
32 EURL-S9.4 ACC - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 ACT - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 CMY - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 DHA - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 FOX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 IMP - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 KPC - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 MOX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 NDM - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 OXA -48 X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 OXA -30 X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 OXA -10 X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 SHV - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 VEB - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 VIM - X PCR (published) ‐ ‐ ‐
32 EURL-S9.4 CTX M-14 PCR (published) ‐ ‐ ‐
32 EURL-S9.4 TEM -1 PCR (published) ‐ ‐ ‐
32 EURL-S9.5 ACC - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 ACT - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 CMY - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 CTX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 DHA - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 FOX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 IMP - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 KPC - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 MOX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 NDM - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 OXA -48 X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 OXA -30 X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 OXA -10 X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 SHV - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 TEM - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 VEB - X PCR (published) ‐ ‐ ‐
32 EURL-S9.5 VIM -2 PCR (published) ‐ ‐ ‐
32 EURL-S9.6 ACC - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 ACT - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 CMY - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 CTX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 DHA - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 FOX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 IMP - X PCR (published) ‐ ‐ ‐
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32 EURL-S9.6 KPC - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 MOX - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 NDM - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 OXA -30 X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 OXA -10 X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 SHV - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 TEM - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 VEB - X PCR (published) ‐ ‐ ‐
32 EURL-S9.6 OXA -48 PCR (published) ‐ ‐ ‐
32 EURL-S9.6 VIM - PCR (published) ‐ ‐ ‐
33 EURL-S9.3 ACC - X PCR (published) Perez‐Perez et al (2002) ACCAGCCTCAGCAGCCGGTTA TTCGCCGCAATCATCCCTAGC
33 EURL-S9.3 ACT - X PCR (published) Perez‐Perez et al (2002) TCGGTAAAGCCGATGTTGCGG CTTCCACTGCGGCTGCCAGTT
33 EURL-S9.3 DHA - X PCR (published) Perez‐Perez et al (2002) AACTTTCACAGGTGTGCTGGGT CCGTACGCATACTGGCTTTGC
33 EURL-S9.3 FOX - X PCR (published) Perez‐Perez et al (2002) AACATGGGGTATCAGGGAGATG CAAAGCGCGTAACCGGATTGG
33 EURL-S9.3 MOX - X PCR (published) Perez‐Perez et al (2002) GCTGCTCAAGGAGCACAGGAT CACATTGACATAGGTGTGGTGC
33 EURL-S9.3 CMY - PCR (published) Perez‐Perez et al (2002) TGGCCAGAACTGACAGGCAAA TTTCTCCTGAACGTGGCTGGC
33 EURL-S9.4 CTX - X PCR (published) Woodford,Fagan, et al. (2006) AAAAATCACTGCGYCAGTTC AGCTTATTCATCGCCACGTT
33 EURL-S9.4 CTX - X PCR (published) Woodford,Fagan, et al. (2006) CGACGCTACCCCTGCT CCAGCGTCAGATTTTTCAGG
33 EURL-S9.4 CTX - X PCR (published) Woodford,Fagan, et al. (2006) TCGCGTTAAGCGGATGATGATGC AACCCACGATGTGGGTAGC
33 EURL-S9.4 CTX - X PCR (published) Woodford,Fagan, et al. (2006) GCACGATGACATTCGGG AACCCACGATGTGGGTAGC
33 EURL-S9.4 OXA - X PCR (published) Fang,Ataker, et al. (2008) ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S9.4 SHV - X PCR (published) Fang,Ataker, et al. (2008) CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S9.4 CTX M-9 PCR (published) Woodford,Fagan, et al. (2006) CCAAGAGARTGCAACGGATG ATTGGAAAGCGTTCATCACC
33 EURL-S9.4 TEM - PCR (published) Fang,Ataker, et al. (2008) CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S9.5 ACC - X PCR (published) Perez‐Perez et al,2002 AAC AGC CTC AGC AGC CGG TTA TTC GCC GCA ATC ATC CCT AGC
33 EURL-S9.5 ACT - X PCR (published) Perez‐Perez et al,2002 TCG GTA AAG CCG ATG TTG CGG CTT CCA CTG CGG CTG CCA GTT
33 EURL-S9.5 CMY - X PCR (published) Perez‐Perez et al,2002 TGG CCA GAA CTG ACA GGC AAA TTT CTC CTG AAC GTG GCT GGC
33 EURL-S9.5 CTX - X PCR (published) Woodford et al,2006 AAA AAT CAC TGC GYC AGT TC AGC TTA TTC ATC GCC ACG TT
33 EURL-S9.5 CTX - X PCR (published) Woodford et al,2006 CGA CGC TAC CCC TGC T CCA GCG TCA GAT TTT TCA GG
33 EURL-S9.5 CTX - X PCR (published) Woodford et al,2006 CAA AGA GAR TGC AAC GGA TG ATT GGA AAG CGT TCA TCA CC
33 EURL-S9.5 CTX - X PCR (published) Woodford et al,2006 GCA CGA TGA CAT TCG GG AAC CCA CGA TGT GGG TAG C
33 EURL-S9.5 CTX - X PCR (published) Woodford et al,2006 TCG CGT TAA GCG GAT GAT GC AAC CCA CGA TGT GGG TAG C
33 EURL-S9.5 DHA - X PCR (published) Perez‐Perez et al,2002 AAC TTT CAC AGG TGT GCT GGG T CCG TAC GCA TAC TGG CTT TGC
33 EURL-S9.5 FOX - X PCR (published) Perez‐Perez et al,2002 AAC ATG GGG TAT CAG GGA GAT G CTT CCA CTG CGG CTG CCA GTT
33 EURL-S9.5 IMP - X PCR (published) Poirel et al,2011 GGAATAGAGTGGCTTAAYTCTC GGTTTAAYAAAACAACCACC
33 EURL-S9.5 KPC - X PCR (published) Poirel et al,2011 CGTCTAGTTCTGCTGTCTTG CTTGTCATCCTTGTTAGGCG
33 EURL-S9.5 MOX - X PCR (published) Perez‐Perez et al,2002 GCT GCT CAA GGA GCA CAG GAT CAC ATT GAC ATA GGT GTG GTG C
33 EURL-S9.5 NDM - X PCR (published) Poirel et al,2011 GGTTTGGCGATCTGGTTTTC CGGAATGGCTCATCACGATC
33 EURL-S9.5 OXA - X PCR (published) Poirel et al,2011 GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG
33 EURL-S9.5 OXA - X PCR (published) Fang et al,2008 ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S9.5 SHV - X PCR (published) Fang et al,2008 CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S9.5 TEM - PCR (published) Fang et al,2008 CGCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S9.5 VIM - PCR (published) Poirel et al,2011 GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG
33 EURL-S9.6 ACC - X PCR (published) Perez‐Perez et al 2002 AAC AGC CTC AGC AGC CGG TTA TTC GCC GCA ATC ATC CCT AGC
33 EURL-S9.6 ACT - X PCR (published) Perez‐Perez et al 2002 TCG GTA AAG CCG ATG TTG CGG CTT CCA CTG CGG CTG CCA GTT
33 EURL-S9.6 CMY - X PCR (published) Perez‐Perez et al 2002 TGG CCA GAA CTG ACA GGC AAA TTT CTC CTG AAC GTG GCT GGC
33 EURL-S9.6 CTX - X PCR (published) Woodford er al,2006 AAA AAT CAC TGC GYC AGT TC AGC TTA TTC ATC GCC ACG TT
33 EURL-S9.6 CTX - X PCR (published) Woodford er al,2006 CGA CGC TAC CCC TGC T CCA GCG TCA GAT TTT TCA GG
33 EURL-S9.6 CTX - X PCR (published) Woodford er al,2006 CAA AGA GAR TGC AAC GGA TG ATT GGA AAG CGT TCA TCA CC
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33 EURL-S9.6 CTX - X PCR (published) Woodford er al,2006 TCG CGT TAA GCG GAT GAT GC AAC CCA CGA TGT GGG TAG C
33 EURL-S9.6 CTX - X PCR (published) Woodford er al,2006 GCA CGA TGA CAT TCG GG AAC CCA CGA TGT GGG TAG C
33 EURL-S9.6 DHA - X PCR (published) Perez‐Perez et al 2002 AAC TTT CAC AGG TGT GCT GGG T CCG TAC GCA TAC TGG CTT TGC
33 EURL-S9.6 FOX - X PCR (published) Perez‐Perez et al 2002 AAC ATG GGG TAT CAG GGA GAT G CAA AGC GCG TAA CCG GAT TGG
33 EURL-S9.6 IMP - X PCR (published) Poirel et al,2011 GGAATAGAGTGGCTTAAYTCTC GGTTTAAYAAAACAACCACC
33 EURL-S9.6 KPC - X PCR (published) Poirel et al,2011 CGTCTAGTTCTGCTGTCTTG CTTGTCATCCTTGTTAGGCG
33 EURL-S9.6 MOX - X PCR (published) Perez‐Perez et al 2002 GCT GCT CAA GGA GCA CAG GAT CAC ATT GAC ATA GGT GTG GTG C
33 EURL-S9.6 NDM - X PCR (published) Poirel et al,2011 GGTTTGGCGATCTGGTTTTC CGGAATGGCTCATCACGATC
33 EURL-S9.6 OXA - X PCR (published) Fang et al,2008 ACACAATACATATCAACTTCGC AGTGTGTTTAGAATGGTGATC
33 EURL-S9.6 SHV - X PCR (published) Fang et al,2008 CTTTATCGGCCCTCACTCAA AGGTGCTCATCATGGGAAAG
33 EURL-S9.6 TEM - X PCR (published) Fang et al,2008 GCCGCATACACTATTCTCAGAATGA ACGCTCACCGGCTCCAGATTTAT
33 EURL-S9.6 VIM - X PCR (published) Poirel et al,2011 GATGGTGTTTGGTCGCATA CGAATGCGCAGCACCAG
33 EURL-S9.6 OXA 48 PCR (published) Poirel et al,2011 GCGTGGTTAAGGATGAACAC CATCAAGTTCAACCCAACCG
41 EURL-S9.3 ACC -1 X PCR (published) ‐ 5'‐AGCCTCAGCAGCCGGTTAC ‐3' 5'‐GAAGCCGTTAGTTGATCCGG ‐3
41 EURL-S9.3 CMY - X PCR (published) ‐ 5'‐ATGCAACAACGACAATCC‐3 5'‐TTGGCCAGCATGACGATG‐3
41 EURL-S9.3 CTX - X PCR (published) ‐ 5'‐ATGTGCAGYACCAGTAARGTKATGGC‐3 5'‐TGGGTRAARTARGTSACCAGAAYSAGCGG‐3'
41 EURL-S9.3 CTX M-1 X PCR (published) ‐ 5'‐CCATGGTTAAAAAATCACTGCG‐3 5'‐TGGGTRAARTARGTSACCAGAAYSAGCGG‐3
41 EURL-S9.3 CTX M-2 X PCR (published) ‐ 5'‐ATGATGACTCAGAGCATTCG‐3' 5'‐GAAACCGTGGGTTACGATTT‐3'
41 EURL-S9.3 CTX M-9 X PCR (published) ‐ 5'‐GTGACAAAGAGAGTGCAACGG‐3' 5'‐ATGATTCTCGCCGCTGAAGCC‐3'
41 EURL-S9.3 IMP - X PCR (published) ‐ 5'‐GGAATAGAGTGGCTTAAYTCTC‐3' 5'‐GGTTTAAYAAAACAACCACC‐3'
41 EURL-S9.3 KPC - X PCR (published) ‐ 5'‐CGTCTAGTTCTGCTGTCTTG‐3' 5'‐CTTGTCATCCTTGTTAGGCG‐3'
41 EURL-S9.3 NDM - X PCR (published) ‐ 5'‐GGTTTGGCGATCTGGTTTTC‐3' 5'‐CGGAATGGCTCATCACGATC‐3
41 EURL-S9.3 OXA -48 X PCR (published) ‐ 5'‐GCGTGGTTAAGGATGAACAC‐3' 5'‐CATCAAGTTCAACCCAACCG‐3
41 EURL-S9.3 TEM - X PCR (published) ‐ 5'‐GCGGAACCCCTATTTG‐3 5'‐ACC AAT GCT TAA TCA GTG AG‐3
41 EURL-S9.3 VIM - X PCR (published) ‐ 5'‐GATGGTGTTTGGTCGCATA‐3' 5'‐CGAATGCGCAGCACCAG‐3
41 EURL-S9.3 CMY -2 PCR (published) ‐ 5'‐ATGATGAAAAAATCGTTATGCTGC‐3 5'‐GCTTTTCAAGAATGCGCCAGG‐3
41 EURL-S9.4 ACC -1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 CMY -2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 CMY - X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 CTX M-1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 CTX M-2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 IMP - X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 KPC - X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 NDM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 OXA -48 X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 VIM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.4 CTX - PCR (published) ‐ ‐ ‐
41 EURL-S9.4 CTX M-9 PCR (published) ‐ ‐ ‐
41 EURL-S9.4 TEM - PCR (published) ‐ ‐ ‐
41 EURL-S9.5 ACC -1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 CMY -2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 CMY - X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 CTX - X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 CTX M-1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 CTX M-2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 CTX M-9 X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 IMP - X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 KPC - X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 NDM - X PCR (published) ‐ ‐ ‐
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41 EURL-S9.5 OXA -48 X PCR (published) ‐ ‐ ‐
41 EURL-S9.5 TEM - PCR (published) ‐ ‐ ‐
41 EURL-S9.5 VIM - PCR (published) ‐ ‐ ‐
41 EURL-S9.6 ACC -1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 CMY -2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 CMY - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 CTX - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 CTX M-1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 CTX M-2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 CTX M-9 X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 IMP - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 KPC - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 NDM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 TEM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 VIM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.6 OXA -48 PCR (published) ‐ ‐ ‐
41 EURL-S9.7 ACC -1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 CMY -2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 CMY - X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 CTX - X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 CTX M-1 X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 CTX M-2 X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 CTX M-9 X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 IMP - X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 KPC - X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 NDM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 OXA -48 X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 VIM - X PCR (published) ‐ ‐ ‐
41 EURL-S9.7 TEM - PCR (published) ‐ ‐ ‐
59 EURL-S9.3 CMY -2 Whole genome sequenced ‐ ‐ ‐
59 EURL-S9.4 CTX M-9 Whole genome sequenced ‐ ‐ ‐
59 EURL-S9.4 TEM -1B Whole genome sequenced ‐ ‐ ‐
59 EURL-S9.5 VIM -2 Whole genome sequenced ‐ ‐ ‐
59 EURL-S9.6 OXA -48 Whole genome sequenced ‐ ‐ ‐
Legend: 
Fields shaded grey indicate that the gene was expected
Genes in bold and white font, were detected but not expected 
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Genotypic characterization (optional); comments by participants
1 S‐9.4 Also contains blaTEM1‐b, which is not a cephalosporinase or a carbapenemase
1 S‐9.5 Also contains blaTEM1‐b, which is not a cephalosporinase or a carbapenemase
17 S‐9.3 The strain was positive for CIT in the Perez‐Perez multiplex. A 1000 bp PCR fragment obtained 
with the Zhao primers was then sequenced.
17 S‐9.4
All other primers references can be found by strain 9.3. We tested for all CTX‐M groups (CTX‐M‐
1g, CTX‐M‐2g, CTX‐M‐9g CTX‐M‐8g). CTX‐9g was positive and sequenced with the primers cited 
above. All other primers references can be found by strain 9.3.
17 S‐9.5
The strain was positive for VIM genes in a PCR multiplex (Dallene et al. JAC 2010), and a 400 bp 
fragment obtained with unpublished primers provided by Y. Pfeifer were sequenced resulting 
VIM‐2. The sequencing of a longer sequence with other primers failed. All other primers 
references can be found by strain 9.3.
17 S‐9.6
The strain was positive for oxa‐48 with the Dallene et al. JAC 2010 multiplex, and then a 744 bp 
PCR fragment obtained wth primers provided by Y Pfeiffer (Aubert et el. J Bacteriol. 2006)was 
sequenced. All other primers references can be found by strain 9.3.
21 S‐9.4 blaCTX‐M group4
32 S‐9.3 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.4 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.5 SPM Gene tested for/not detected (L. Poirel et al 2011)
32 S‐9.6 SPM Gene tested for/not detected (L. Poirel et al 2011)
33 S‐9.3 As CMY belongs to the CIT Group we would prefere to have that choice as we use a Muliplex 
PCR. Why is not the CIT Group listed?
41 S‐9.3 The genes SPM and BIC were tested, but they did not detected
41 S‐9.4 The genes SPM and BIC were tested, but they did not detected
41 S‐9.5 The genes SPM and BIC were tested, but they did not detected
41 S‐9.6 The genes SPM and BIC were tested, but they did not detected
41 S‐9.7 The genes SPM and BIC were tested, but they did not detected
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